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Functional Imaging to enable more accurate localisation and characterisation of prostate 
tumours  
 
Abstract 
 
Prostate cancer is the leading cause of cancer death in men after skin cancer, with an 
incidence expected to double by 2030 mainly due to the ageing population. However, many 
more men die with prostate cancer rather than from the disease, highlighting the indolent 
nature of many tumours. Therefore, the development of non-invasive imaging methods to 
stratify prostate cancer is important for patient management. 
 
Recently, multiparametric MRI has revolutionised the work-up of prostate cancer, becoming 
a routine part of clinical practice and migrating earlier in the diagnostic pathway. However, 
the technique remains challenging, with patient-related factors, intrinsic insensitivity of 
MRI, protocol differences, and radiologist experienced all combining to limit its overall 
accuracy. Anatomical T2-weighted imaging is limited by the non-specific nature of its 
findings and improvements have mainly been driven by the addition of functional sequences 
such as diffusion-weighted imaging, dynamic contrast-enhanced MRI and spectroscopy. In 
the absence of validated circulating biomarkers, only functional imaging currently offers the 
potential for further improvements in lesion detection and characterisation, with the 
additional advantages of providing whole gland coverage of the prostate and being non-
invasive. 
 
This thesis addresses the issues of prostate tumour localisation and characterisation using 
functional imaging techniques. Chapter 2 assesses whether simple pre-imaging 
interventions relating to patient preparation can help improve MRI quality. Chapter 3 
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evaluates the potential for two novel functional MR sequences to differentiate tumour from 
normal prostate tissue. Chapter 4 investigates whether non-proton sodium MRI can offer 
functional information reflecting cell membrane integrity and cell viability. Chapter 5 
evaluates whether the PET/CT tracer 11C-acetate can offer additive information on primary 
prostate tumours. 
 
Tristan Barrett 
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Chapter 1: Background 
This chapter provides an overview of prostate cancer incidence and epidemiology, the 
current clinical work-up of the disease in the UK and its limitations, the sequences that form 
part of multiparametric (mp) MRI of the prostate, and the evolving role of MRI in the 
diagnostic pathway.  
 
1.1 Epidemiology of prostate cancer 
Prostate cancer (PCa) is the most common non-cutaneous malignancy in men worldwide, 
and accounts for almost 1-in-5 of all new male cancer diagnoses [1]. In 2014 there were 
46,690 new cases in the UK, with the global incidence of the disease expected to double by 
2030, in part due to the ageing population [2, 3]. Despite the high incidence overall, 
prognosis is good with cancer-specific survival being 84% at 10 years [2].  
 
In 1986 the US Food and Drug Administration (FDA) approved the prostate-specific antigen 
(PSA) test for monitoring PCa progression, and in 1994 approved its use alongside digital 
rectum examination (DRE) to test asymptomatic men. This introduction led to a spike in 
incidence in the early 1990s (Figure 1.1) due to a surge in the detection of asymptomatic 
disease [4]. The name PSA is a misnomer as it is not specific to the prostate and is known to 
be produced in the lung and salivary glands, and may even be expressed by breast, ovarian 
and endometrial tumours [5]. Moreover, it is not specific to cancer of the prostate and can 
be raised in benign prostatic hypertrophy (BPH), inflammation, infection, and trauma.  
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Figure 1.1. Surveillance, Epidemiology, and End Results (SEER) program: US men prostate 
cancer incidence and mortality [14] 
 
 
Several screening studies have attempted to quantify the benefit of PSA as a screening test, 
the largest being the USA Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening 
trial and the European Randomized Study of Screening for Prostate Cancer (ERSPC). The 
PLCO study reported more diagnoses of PCa in the screened group at 10 years, but with a 
similar death rate in each arm [6]. Although an upper limit of normal PSA is quoted as 4.0 
ng/ml for men aged over 60 years, many men with PSA below this threshold will have 
cancer, and PSA therefore represents a continuum of risk at all values [7]. The sensitivity 
and specificity of a raised PSA at >4.1 ng/ml is 20% and 94%, respectively [8]; this low 
sensitivity arguably means PSA fails the primary goal of a screening test, namely detecting 
cancer. Current European and US guidelines from the Preventive Services Task Force 
(USPSTF) therefore do not recommend population screening for prostate cancer [9]. More 
recently the incidence of prostate cancer in the US has declined dramatically and by more 
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than 10% annually from 2010 to 2013, which is likely to relate directly to the USPSTF 
recommending against routine use of PSA for screening purposes [1]. However, the USPSTF 
recently recommended that PSA can be selectively offered to men aged 55 to 69 years, 
depending on individual circumstances, professional judgment and patient preferences, as 
they consider there to be at least moderate certainty of the net benefit being small 
(category C) [10]. PSA-based screening for prostate cancer continues to be discouraged for 
men age 70 years and older (category D). It remains to be seen how this impacts on prostate 
cancer diagnosis. 
 
1.2 Potential for over-diagnosis 
While 1-in-6 men are diagnosed with prostate cancer, only 1-in-36 will die from the disease 
[11]. This highlights the indolent nature of many of the tumours currently diagnosed and it 
remains true that many more men will die with prostate cancer than directly because of the 
disease.  
 
The introduction of PSA testing dramatically changed the profile of patients presenting with 
prostate cancer. The average age at presentation reduced from 64 to 59 years, index lesion 
volume reduced by more than 50% with fewer tumours therefore detectable by DRE, and 
the majority now present with low risk rather than high risk disease [12]. Additionally, soon 
after widespread PSA use, the average PSA level at presentation had reduced from 25 to 8 
ng/ml, whilst the average gland volume increased from 44 to 53 cm3, meaning that a raised 
PSA at baseline shifted from being indicative of cancer to being more likely to be due to BPH 
[13]. The implication is that this practice has led to the over-diagnosis of clinically 
insignificant cancer that would not otherwise have resulted in symptoms or cancer-related 
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death [14]. Indeed, whilst the overall incidence of prostate cancer has declined over the last 
10 years, the rates for higher stage and distant disease have been stable in the same period 
[15], suggesting it is the diagnosis of indolent disease that has been reduced. However, 
there remains the risk that current urological practice may serve to exacerbate the problem 
of over-diagnosis. Repeating PSA tests, using a lower PSA threshold for performing prostatic 
biopsy, taking more cores at biopsy, and repeating a biopsy after initial negative results, are 
all factors which are likely to lead to a further increase in the incidence of lower grade, 
smaller volume, and relatively indolent cancer [12]. 
 
1.3 Risk of over-treatment 
Over-diagnosis in itself is not a problem, but this potentially leads to over-treatment of 
indolent disease, which is an issue due to the associated risk of significant morbidity. The 
traditional radical treatment of prostate cancer with either prostatectomy or external beam 
radiation therapy carries with it a 50-60% risk of erectile dysfunction and, although the rates 
of severe urinary incontinence are low, as many as 30% continue to report some symptoms 
at long-term follow-up [16-18].  
 
It is estimated that in screen-detected populations, 48 men will need to undergo treatment 
to prevent 1 prostate cancer death [19]; this ratio compares unfavourably with breast 
cancer screening programs where 3 patients need treatment to prevent 1 death [20]. 
Indeed, the USPSTF recommendations against PSA for screening purposes are mainly based 
on these growing concerns about over-treatment [9].  
 
Active surveillance (AS) has recently emerged as a means of addressing such over-treatment 
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and is now recommended as the management strategy of choice in men with low-risk 
localized prostate cancer for whom radical therapy remains a clinical option [21]. This 
approach is supported by Level 1 evidence that not all men diagnosed with prostate cancer 
need active treatment, and that radical curative therapy only benefits those with more 
aggressive, high-risk disease [22, 23]. The Prostate Cancer Intervention Versus Observation 
Trial (PIVOT) was the first well controlled trial to assess the impact of radical prostatectomy 
compared with observation and suggests that for patients with low risk disease (diagnosed 
by systematic TRUS biopsy) or PSA ≤ 10, treatment does not confer a prostate-cancer 
mortality advantage, however, those with higher risk disease would benefit from 
intervention [22]. A recent update of the PIVOT trial at longer term follow-up, suggests that 
surgery may also be associated with lower all-cause mortality than observation among men 
with intermediate-risk disease [24]. 
 
1.4 Risk of under-treatment 
Prostate cancer is almost unique amongst solid organ tumours in that it is predominantly 
diagnosed by an indirect, non-targeted method. The standard diagnostic test for clinically 
suspected prostate cancer remains transrectal ultrasound (TRUS) guided biopsy. The biopsy 
needle is “guided”, but only to the prostate gland rather than to a tumour and 
systematically under-samples the anteriorly gland, the midline and the extreme apex. 
Ultimately only 1% of the gland is sampled and therefore TRUS biopsy is unsurprisingly 
prone to sampling error [25]. It is well established that TRUS biopsy underestimates 
aggressiveness in around one-third of cases [26], underestimates volume in one-half of 
cases, and may miss up to 50% of clinically significant tumours [27]. Therefore, whilst over-
treatment is a concern there is also a real risk of traditional diagnostic pathways resulting in 
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under-treatment due to misclassifying cancers as being less aggressive or incorrectly 
categorizing patients as being tumour free.  
 
1.5 Role of Imaging in Prostate Cancer 
Given this potential for both under- and over-treatment, there needs to be a rethink in how 
patients are assessed diagnostically. There are several blood tests available that may serve 
as indicators of prostate cancer including PCA-3, the 4K score test, and the Prostate health 
index, with increasing excitement about a potential role for circulating tumour DNA [28, 29]. 
However, there are currently no blood or urine-based biomarkers that can reliably locate 
the presence of a high-grade aggressive tumour in the prostate [29]. Realistically, imaging 
offers the greatest potential of differentiating these more aggressive, lethal cancers. 
 
Imaging has traditionally performed a limited role of staging in higher risk tumours with MRI 
being used for local staging and CT or bone scintigraphy for nodal and bone metastases. 
However, multi-parametric MRI (mp-MRI), incorporating multi-planar T2-weighted, and 
functional DCE and diffusion-weighted imaging, has now been validated as a means of 
detecting prostate tumours [30, 31]. 
 
Alongside accurate risk stratification of prostate tumours, another driver to improved 
tumour detection and localisation is to aid biopsy targeting. Current UK guidelines 
recommend that mpMRI be performed in high risk patients following a negative systematic 
TRUS biopsy in order to target subsequent repeat biopsy [32]. A recent meta-analysis 
demonstrated that in the re-biopsy population, mpMRI increased the detection rates of 
significant cancers by 54% and reduced insignificant (indolent) cancer detection by 18% [33]. 
20 
 
As a result, some authors even suggest that MRI should replace TRUS biopsy as the initial 
diagnostic test for prostate cancer to enable guidance of subsequent biopsy [34]. However, 
the data is less convincing in biopsy naïve patients, where mpMRI guided prostate biopsy 
only marginally increases the detection rates of significant disease by 10%, although it 
remains of benefit in reducing insignificant cancer detection by 49% [33]. This diagnostic 
gain has to be balanced against the restrictions of the UK national 31-day time-to-diagnosis 
targets and difficulty in obtaining an MRI at short notice. Reserved MRI slots may be difficult 
to justify if (even occasionally) they are left unfilled given that MRI is a relatively scarce 
resource. 
 
Nevertheless, several UK centres have implemented MRI pre-biopsy over and above 
national guidelines. The 2017 update of the National Prostate Cancer Audit suggests that in 
men who do undergo MR imaging for prostate cancer, this is being performed prior to first 
biopsy in 73% of cases [35]. Indeed, the London Cancer Alliance Best Practice Prostate 
Pathway has highlighted pre-biopsy MRI as a key component of delivering prostate cancer 
diagnosis and treatment within the 62 day national cancer target [36]. Pre-biopsy prostate 
MRI is not appropriate for all patients, but is indicated in candidates for radical curative 
treatment when there is a palpable abnormality on DRE, or in men with two raised PSA 
measurements, or high clinical suspicion of prostate cancer, or to potentially avoid the 
adverse effects of biopsy, if considered to be of high risk. The recently published Prostate 
MRI Imaging Study (PROMIS) supports this practice and is likely to influence future UK 
guidelines [37]. PROMIS demonstrated that mpMRI in biopsy-naïve patients outperforms 
systematic TRUS biopsy, the current standard of care. As a triage test, mpMRI could 
potentially avoid unnecessary biopsy in 27% of patients, whilst diagnosing up to 18% more 
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cases of clinically significant cancer and 5% fewer clinically insignificant cancers.  Clearly the 
increased use of MRI in biopsy naïve patients brings additional challenges, with the 
emphasis of radiological interpretation shifting from one of basic staging to lesion detection 
and characterisation in order to direct subsequent sampling. 
 
1.6 What is prostate multiparametric MRI? 
Multiparametric (mp) MRI of the prostate is the addition of functional imaging to standard 
anatomical T1 and T2-weighted imaging [38]. The available functional sequences include 
diffusion-weighted imaging (DWI) with calculation of apparent diffusion coefficient (ADC) 
maps, dynamic contrast-enhanced (DCE) MRI, and spectroscopic imaging.  
 
Anatomical T2 weighted imaging was the earliest available sequence and remains the 
optimal sequence for assessment of the transition zone (TZ). Its value in the peripheral zone 
(PZ) where tumour appears as low signal intensity is more limited due to a number of 
benign conditions which mimic this appearance, including prostatic intraepithelial neoplasia 
(PIN), prostatitis, haemorrhage, atrophy, scarring, and post-treatment change [39]. 
 
DWI is an MR technique that images the diffusion of water molecules and does not require 
administration of an exogenous contrast agent. Tumours will typically demonstrate 
restricted diffusion due to increased cellularity preventing extracellular diffusion of water 
and an increased nuclear:cytoplasmic ratio, which limits intracellular diffusion. An absolute 
restriction limit cannot be reached in extracranial tissues and thus the term “impeded” 
rather than “restricted” diffusion is more physiologically correct for body DW imaging, 
however, the term “restricted diffusion” will be used throughout this thesis due to its 
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widespread adoption in the existing literature. 
 
DCE-MRI requires intravenous administration of a low molecular weight Gadolinium chelate. 
Tumours form their own blood vessels once they grow above a certain size, with this neo-
angiogenesis being disorganised, leading to porous endothelia. Gadolinium rapidly washes-
into the tumour interstitium, being visualised as early signal change due to contrast 
enhancement, and then washes-out. Analysis of DCE MRI curves is effective in breast 
disease as the pattern can differentiate benign and malignant lesions -  a Type I curve (slow, 
late, continuous enhancement) is rarely associated with malignancy (~9%), whereas a Type 
3 pattern (early enhancement with peak and wash-out) has a 90.4% specificity for cancer 
[40]. However, this “curvology” based approach does not work well in the prostate because 
benign conditions such as prostatitis and hypervascular BPH nodules can have a Type 3 
curve, and overall it is more common for tumours to demonstrate a Type 2 curve (early 
enhancement and plateau) making it difficult to accurately differentiate malignancy [41]. As 
a result, the role of DCE-MRI has been significantly downplayed in the Prostate Imaging 
Reporting and Data System (PI-RADS) guidelines, version 2 and only concentrates on the 
wash-in phase [42]. 
 
MR spectroscopy is challenging, often requiring significant post-processing and additional 
input from MR physicists. The paradigm is based on tumour cell proliferation and cell 
membrane turnover leading to an increased amount of choline, with a corresponding 
reduction in citrate levels, a metabolite produced by the normal prostate and therefore a 
marker of benign tissue. The low sensitivity (16%) makes spectroscopy poor for lesion 
detection, and although it has an excellent specificity (approaching 100%) and can improve 
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lesion characterisation, the incremental benefit is comparatively small [43], in particular 
relative to the step-wise increase in costs incurred [44]. As a result, the most recent version 
of the PI-RADS guidelines (version 2) has dropped spectroscopy and “mpMRI” therefore 
should incorporate T2-weighted imaging, DWI and DCE-MRI [41]; Figure 1.2. Despite this, a 
recent National Prostate Cancer Audit in the UK highlighted the fact that although 99% of 
hospitals in England have access to on-site MRI only 75% are providing mpMRI [45]. 
 
 
Figure 1.2 Standard clinical mpMRI diagnostic sequences. 73 year old patient, PSA 9.85 ng/ml, MRI 
performed pre-biopsy. High probability (PI-RADS score 5) 19×10 mm lesion in the left mid PZ 
(arrows). Lesion demonstrates focal low T2 signal (A), early enhancement on DCE compared to 
contralateral PZ (B), high signal on b-2000 DWI (C), and low signal on ADC maps (D). Targeted biopsy 
revealed Gleason 3+4 disease in 50% and 13 mm of all 3 cores, maximum tumour length 9 mm. 
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1.7 Prostate Imaging Reporting and Data System (PI-RADS) 
MR imaging is in general less reproducible between centres than CT, plain film or 
ultrasound. The reasons are multifactorial and include the magnet strength, coil technology 
(endorectal coil versus body coil, number of elements), software version being run and 
protocol set-up (e.g., choice of b-values for DWI). This makes inter-centre comparison 
challenging, particularly for quantifiable measurements derived from DWI and DCE-MRI. 
Other inter-patient factors that may be difficult to control include artefact due to hip 
metalwork, prior biopsy, rectal loading, and tumour-specific factors including a sparse 
growth pattern [46]; Table 1.1. 
 
 
 
Technical Factors 
 
 
Patient-related Factors 
 
 
The prostate is a small organ 
 
Biopsy-related artefact 
Magnet strength (1.5 versus 3T) Previous treatment 
Coil used (body versus endorectal) Patient motion 
Vendor-related differences Rectal loading and spasm 
Number of b-values selected and their value Hip metalwork 
Software upgrades 
 
 
Normal structures mimicking PCa 
 
Tumour-related Factors 
 
 
Radiologist Factors 
 
Grade of lesion 
 
Subjective interpretation 
Size of lesion Experience/known learning curve 
Sparse pattern of growth 
 
Reporting standardisation 
 
Table 1.1 Factors that make mpMRI interpretation challenging 
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Another variable to consider is the experience of the radiologist. We reviewed our prostate 
MR interpretation and outcomes based on template transperineal biopsy performed locally 
and demonstrated a significant increase in cancer detection from 27% to 63%, with a 
concurrent increase in NPV from 66.6% to 88.9% during a defined learning curve period 
[47]. There is no data on how many prostate MRIs should be reported to reach the top of 
this learning curve, but anecdotally 100-150 reports need to supervised and with pathology 
feedback to achieve an appropriate competence [48]. Beyond this it is recommended that 
radiologists report at least 50 mpMRIs per year, audit their results, and regularly attend 
MDT meetings in which outcomes are discussed, in order to maintain competency levels 
[34]. 
 
It is with these MRI protocol-related and radiologist-specific factors in mind that the 
European Society of Urogenital Radiology (ESUR) in 2012 first devised recommendations 
based on consensus expert opinion aimed at standardising the acquisition, interpretation 
and reporting of prostate MRI [49]. These guidelines were modelled on similar efforts in 
mammography (BI-RADS) that led to the transformation of breast cancer care and became 
popularly known as “Prostate Imaging-Reporting and Data System” (PI-RADS). Subsequent 
studies validated PI-RADS in certain research and clinical settings, however, experience also 
highlighted limitations, in part due to technical improvements. A joint steering committee 
formed by the American College of Radiology ESUR, and the non-profit organisation 
AdMeTech Foundation, updated the original guidance, with PI-RADS version 2 made 
available in early 2015 [50]. The key changes related to MRI acquisition, with spectroscopy 
being dropped and a single acquisition protocol being recommended and to MRI 
interpretation, with the concept of a dominant sequence, namely DWI in the PZ and T2WI in 
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the TZ and secondary sequences (DCE in the PZ and DWI in the TZ) which can upgrade a 
score “3” to a score “4”. The sequence-specific scoring system is summarised below (Table 
1.2), with the dominant sequence principle being applied in order derive an overall PI-RADS 
score of 1-5 for tumour probability, wherein 1 = very low (clinically significant cancer is 
highly unlikely to be present), 2 = low (clinically significant cancer is unlikely to be present), 
3 = intermediate (the presence of clinically significant cancer is equivocal), 4 = high (clinically 
significant cancer is likely to be present), 5 = very high (clinically significant cancer is highly 
likely to be present).  
 
  
27 
 
 
T2W for Peripheral Zone 
 
   1         Uniform high signal intensity 
 
   2         Linear, wedge shaped, or geographic areas of lower SI, usually not well demarcated 
 
   3         Heterogeneous signal intensity or non‐circumscribed, rounded, moderate hypointensity. Or  
              other not in categories 1/2 or 4/5 
    
   4         Circumscribed, homogenous moderate hypointense focus/mass confined to prostate and  
              <1.5 cm in greatest dimension 
 
   5          Same as 4 but ≥1.5cm in greatest dimension or definite ECE/invasive behaviour 
 
      
T2W for Transition Zone 
 
   1          Heterogeneous intermediate SI 
 
   2          Circumscribed hypointense or heterogeneous encapsulated nodule(s) (BPH) 
 
   3          Heterogeneous signal intensity with obscured margins. Or other not in categories 1/2 or 4/5 
 
   4          Lenticlular or non‐circumscribed, homogeneous, moderately hypointense, and <1.5 cm in  
               greatest dimension 
 
   5          Same as 4, but ≥ 1.5cm in greatest dimension or definite ECE /invasive behaviour 
  
 
Diffusion-weighted Imaging 
 
   1          No abnormality (i.e. normal) on ADC and high b‐value DWI 
 
   2          Indistinct hypointense on ADC 
 
   3          Focal mildly/moderately hypointense on ADC and isointense/ mildly hyperintense on high  
               b‐value DWI 
 
   4          Focal markedly hypontense on ADC and markedly hyperintense on high b‐value DWI; <1.5cm in           
               greatest dimension 
 
   5          Same as 4 but ≥1.5cm in greatest dimension or definite ECE / invasive behaviour 
 
 
Dynamic contrast-enhanced MRI 
 
   -          No early enhancement   OR 
              Diffuse enhancement not corresponding to a focal finding on T2 and/or DWI   OR 
              Focal enhancement corresponding to a lesion demonstrating features of BPH on T2WI 
 
   +         Focal   AND  
              Earlier than or contemporaneously with enhancement of adjacent normal prostatic tissues  AND 
              Corresponds to suspicious finding on T2 and/or DWI 
 
 
Table 1.2. PI-RADS version 2 sequence-specific scoring systems. ECE = Extra-Capsular Extension, 
BPH = Benign Prostatic Hypertrophy, ADC = apparent diffusion co-efficient, DWI = Diffusion-
Weighted Imaging 
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1.8 How good is prostate mpMRI?  
Although anatomical T2-weighted imaging complemented by functional diffusion-weighted 
imaging can be used for lesion detection, current mpMRI has inherent limitations, and the 
technique performs particularly poorly for detection of lower grade lesions, or those <0.5 
cm3 in size [51]. Studies report considerable variability, with sensitivity for cancer detection 
ranging from 53-100% and specificity 32-97%, and being dependant on the composition of 
the cohort selected, the gold standard employed, and technical factors [52-54].  
 
A systematic review incorporating studies published up to February 2012, and therefore 
prior to the introduction of PI-RADS, showed MRI to have a pooled sensitivity of 74% and 
specificity of 88% [55]. A more recent PI-RADS era review of 21 studies (3,857 patients) 
published in 2015-2016, with all patients being imaged after 2010, showed mpMRI to have a 
sensitivity of 89% and specificity 74% for high probability lesions [52]. In studies directly 
comparing PI-RADS versions 1 and 2, it is noteworthy that version 2 resulted in an increased 
sensitivity (95% compared to 88%), without a reduction in specificity. This may relate to the 
improved inter-observer agreement demonstrated with PI-RADS version 2, particularly in 
the PZ [56, 57]. These results are supportive of the changes implemented in version 2, and 
may reflect removal of MR spectroscopy, which is known to have a high specificity, enabling 
lesion characterisation, but has a reported sensitivity as low as 16%, limiting lesion 
detection [43]. The increase in sensitivity at the expense of specificity is beneficial clinically, 
particularly if MRI is to be used to avoid biopsy. To this end, the negative predictive value of 
mpMRI as a rule-out test in a systematic review of 48 studies (9,613 patients) was reported 
to be 82.4% for any cancer and 88.1% for Gleason ≥3+4 cancer [58]. This compares 
favourably to the current “gold standard” of systematic TRUS biopsy with an NPV of around 
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75% for clinically significant cancer [37]. It should be noted, however, that NPV is not 
intrinsic to the test itself and will vary depending on the cancer prevalence within the 
cohort. The same review reported NPV to range 68.4-100%, with a close inverse correlation 
to cancer prevalence of 13-74.7% [58], and Woo et al [52] noted a specificity for cancer 
detection of only 65% in studies where cancer prevalence was below 50%, but rising to 86% 
when >50%. In should also be noted that studies within the literature need to also be 
considered in terms of heterogeneity of the patient population, the gold standard employed 
(a surgical cohort will introduce bias such as operative suitability), and the exclusion criteria 
applied, such as presence of MRI artefact, haemorrhage or metalwork, meaning these may 
not necessarily be reflective of a standard clinical reporting list.   
 
1.9 Chapter summary 
In this chapter the epidemiology and work-up of prostate cancer has been introduced and 
discussed. It has been demonstrated that PSA testing has dramatically changed the profile 
of men presenting with prostate cancer which brings the risk of over-diagnosing and over-
treating relatively indolent disease. Contrary to this there is a real risk of under-treatment 
due to the limitations of the traditional diagnostic pathway resulting in under-grading or 
missing tumours. Imaging with mpMRI has a potential role to play in mitigating these risks, 
with MRI having evolved from morphological staging to more accurate localisation of 
tumours and being used earlier in the diagnostic pathway.  
 
However, mpMRI is a difficult technique to perform and interpret and has its own inherent 
limitations, highlighting the need for improvement in the existing sequences, or use of 
further novel functional sequences. Indeed, the most recent version of the PI-RADS 
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guidelines strongly supports the continued development of novel sequences. In the absence 
of reliable blood or urine markers biomarkers, realistically imaging offers the greatest 
potential for differentiating more aggressive, lethal cancers. To achieve this we need to 
image tumour function rather than structure, and currently PET imaging and novel MRI 
functional sequences offer the only means of adding incremental value to the existing 
clinical mpMRI sequences. 
 
In this thesis, the optimisation of existing mpMRI sequences will be assessed and the issues 
of prostate tumour localisation and characterisation using novel functional imaging 
techniques assessed, with the ultimate aim of enabling more accurate prostate cancer 
stratification to inform management decisions. 
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Chapter 2: Optimising patient preparation for prostate mpMRI 
 
2.1 Introduction 
The difficulty of performing and interpreting prostate mpMRI has been highlighted and may 
related to patient, tumour, MR scanner and radiologist factors. Patient-related factors may 
be partially mitigated by ensuring patient preparation is optimised, however, the current 
version of the PI-RADS guidelines states that:  
 
“At present, there is no consensus concerning all patient preparation issues.” [1] 
 
Nevertheless, three potentially controllable areas are highlighted:  
- Use of antispasmodic agents to reduce motion artefact from bowel peristalsis 
- Presence of air and/or stool in the rectum that may induce distortion on DWI 
- Refraining from ejaculation prior to MRI to maximise seminal vesicle distention 
 
In order to inform whether these factors impact on MR image quality we assessed the first 
two of these issues in a retrospective study of clinical  mpMRI and the third by means of a 
prospective normal volunteer study. 
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2.2 Retrospective assessment of patient preparation on prostate multiparametric MRI 
image quality 
 
A retrospective study was designed to assess for effect of both hyoscine butylbromide (HBB) 
and rectal loading on image quality [2, 3].  
 
2.2.1 Study population 
This single-institution retrospective study was approved as part of a prostate MRI service 
evaluation, with the need for informed consent for data analysis waived by the local ethics 
committee (study registration CUH/15/5126). The study comprised 173 patients undergoing 
3T prostate MRI for any indication during a 12 month window, from March 2015 – February 
2016. Exclusion criteria included previous treatment for prostate cancer and presence of 
pelvic metalwork.  
 
HBB is routinely administration for prostate MRI unless clinically contraindicated. During the 
study period, approximately four times as many patients received HBB, therefore every 
fourth patient was selected to match numbers, with 87 in the HBB group and 86 in the non-
HBB group. Patients in the HBB group were administered 20 mg of intravenous hyoscine 
butylbromide (Buscopan®, Boehringer, Ingelheim, Germany) on the table, immediately prior 
to scanning. 
 
2.2.2 Magnetic Resonance Imaging  
Patients underwent MRI at 3T (MR750, GE Healthcare) using a 32 channel phased array 
cardiac coil. Sequences included axial T1 weighted FSE (fast spin echo) pelvic images and 
38 
 
high resolution T2 weighted fast recovery FSE images of the prostate in the axial, sagittal, 
and coronal planes. T1 weighted parameters: TR/TE 561/11ms, FOV 24 × 24 cm, resolution 
1.1 x 1.0mm. T2 weighted parameters: TR/TE 4273/102ms, FOV 22 x 22 cm, resolution 0.8 x 
0.7mm, 1.5 signal averages. Axial diffusion-weighted imaging (DWI) was performed using a 
dual spin-echo planar pulse sequence: TR/TE 3775/70ms, FOV 28 × 28 cm, resolution 2.2 x 
2.2mm, with 6 signal averages; b-values of 150, 750, 1400 and 2000 s/mm2, with automated 
ADC maps. Axial 3D dynamic contrast-enhanced (DCE) images were acquired using a fast-
spoiled gradient echo sequence (TR/TE 4.088/1.788ms; FOV 24 x 24 cm) with a temporal 
resolution of 7s. After 28s a bolus of Gadobutrol (Gadovist, Schering AG) was injected via a 
power injector at 3 mL/s (dose 0.1 mmol/kg) followed by a 25 mL saline flush at 3 ml/s. The 
axial T2-w, DWI and DCE sequences were spatially matched, with a 3 mm thickness and 0-
mm gap.  
 
2.2.3 Image analysis  
Images were reviewed for image quality by two radiologists, blinded to the clinical details. 
Planimetry rectal volumes were derived using maximal axial and sagittal dimensions (anal 
canal to peritoneal reflection), and a subjective assessment of rectal distension was made 
using a 5-point Likert scale: 1 = no stool/gas, 2 = minimal, 3 = small amount, 4 = moderate, 5 
= large amount of stool/gas. T2-weighted imaging was qualitatively assessed for image 
sharpness (based on the sharpness of the neurovascular bundle, seminal vesicles, and 
prostatic capsule compared to periprostatic fat) and motion artefact (ghosting or 
movement). DW image quality was scored on the highest b-value imaging (b=2000 s/mm2) 
using a 5-point scale: poor = 1, suboptimal = 2, adequate = 3, above average = 4, excellent = 
5. DWI was also assessed for artefact and distortion using 4-point scales; artefact: none = 1, 
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mild, not/mildly impacting diagnosis = 2, artefact moderately impacting diagnosis = 3, 
marked artefact/non-diagnostic = 4; distortion: none = 1, <5mm mismatch to T2WI = 2, ≥5 
mm mismatch to T2WI or mild warping = 3, significant warping = 4. DCE images were 
assessed based on the number of corrupt data points, using a region-of-interest of ≥0.2cm3 
in normal appearing peripheral zone, and recording the number of corrupted data points 
from the contrast curve (defined as any >10%, between-point, signal intensity changes 
during the wash-out phase). 
 
2.2.4 Statistics  
The Shapiro-Wilks test was used to assess distributional normality. Non-parametric 
distributions were reported using median and inter-quartiles (IQ). Chi-square test (Χ2) was 
performed to compare MRI indications against HBB grouping. Wilcoxon signed ranked tests 
were performed to assess differences between binary criteria (T2 motion and sharpness) 
and the ordinal image quality scales. Fisher’s exact test was used to compare targeted 
biopsy outcomes between groups of patients with differing rectal distension. Spearman’s 
correlation was performed to assess the relationship between ordinal variables. A p-value 
<0.05 was defined as statistically significant. Weighted Cohen’s Kappa was performed to 
assess inter-rater agreement using the following rules of thumb (0–0.20 = slight, 0.21–0.40 
fair, 0.41–0.60 moderate, 0.61–0.80 substantial, and 0.81–1 almost perfect agreement). The 
statistical analysis was performed using R (version 3.1.1, The R Foundation for Statistical 
Computing, Vienna, Austria).  
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2.2.5 Results  
A total of 173 patients were included with a median age of 65 years (mean 63.8, range 59 - 
69) and a median PSA of 6.57 (mean 6.78, range 4.17 - 10.02).  
 
2.2.5.1 Hyoscine butylbromide administration 
Administration of HBB significantly improved the image quality of T2-weighted images 
compared to the non-HBB group (3.63±1.11 versus 2.84±0.899); p<0.001 (Table 2.1, Figure 
2.1). The HBB group showed significantly less T2W motion and blur than the non-HBB group 
(23.0% and 51.7% versus 53.5% and 83.7%, respectively; p<0.001). However, there was no 
significant improvement in DWI/ADC image quality, distortion or artefact. There was a trend 
towards fewer corrupted DCE data points in the HBB group (2.47±2.44 versus 3.68±2.64), 
but this did not reach significance (p=0.052). There was no difference in rectal volumes or 
planimetry measurements between the groups (p = 0.141 - 0.206).  
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 HBB No HBB p-value 
    
T2W Imaging (n=87) (n=86)  
    
Image Quality (± SD) 3.63±1.11 2.84±0.89 <0.001* 
Motion Present  20 (23.0%) 46 (53.5%) <0.001* 
Blur Present 45 (51.7%) 72 (83.7%) <0.001* 
    
DWI (n=87) (n=86)  
    
Image Quality (± SD) 3.53±1.03 3.27±0.91 0.091 
Distortion (± SD) 2.20±0.93 2.43±0.90 0.078 
Artefact (± SD) 1.60±0.56 1.64±0.59 0.692 
    
ADC    
    
Image Quality (± SD) 3.74±1.07 3.57±0.98 0.220 
    
DCE (n=34) (n=33)  
    
Corrupt data points 
(± SD) 
2.47±2.44 3.68±2.64 0.052 
    
Table 2.1: Image Quality scoring comparing hyoscine N-butybromide versus non-HBB groups for 
different MRI sequences. * Denotes a significant difference. SD = standard deviation. 
 
 
 
 
Figure 2.1: MR image quality relating to HBB administration. (A) Image blur on T2WI: 57 year old, 
Gleason 3+3 disease on active surveillance, PSA 2.7 ng/ml. Indistinct capsule and prostatic zone 
interface. No HBB given due to history of cardiac arrythmia. (B) Image motion on T2WI: 58 year old, 
PSA 5.3, MRI pre-biopsy. HBB not given due to lack of medical cover. Ghosting artefact noted within 
the bladder. (C) T2W image of good quality: 64 year old, PSA 5.1, MRI performed pre-biopsy, HBB 
given. T2W image quality rated as 5/5 by both readers, with no blur and no motion. 
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2.2.5.2 Rectal loading 
The inter-reader agreement for subjective scoring of rectal loading expressed using Cohen's 
kappa coefficient was 0.819 indicating excellent agreement between the two readers. A 
significant correlation was shown between increased rectal distension and both reduced 
DW image quality (r = -0.628, p<0.001), and increased DW image distortion (r=0.814, 
p<0.001). Increased rectal distension led to increased motion artefact on T2 (p = 0.0096), 
but there was no effect on DCE image quality (Figure 2.2). There was a strong correlation 
between subjective scoring of rectal loading and objectively measured AP diameter (r = 
0.882) and rectal volume (r = 0.82), p<0.001 
 
Figure 2.2: Marked rectal loading with significant effect on T2 and DW image quality. 66 year-old, 
PSA 5.63, MRI performed pre-biopsy. Subjective scores of severe rectal loading (A). B: T2 imaging 
scored as loss of sharpness and presence of motion artefact. C: DWI shows significant warping. 
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2.2.6 Discussion 
The results of our study show that the quality of T2W images was significantly improved 
patients receiving hyoscine butylbromide. In addition, increasing rectal distension has been 
shown to have a significant negative effect on the quality of both T2W and DW images.   
 
The results for HBB administration improving T2W image quality are concordant with the 
study by Kier et al at 1.5T showing significantly less artefacts when the glucagon was given 
as an anti-spasmotic agent (7% vs. 45%) [4]. Similarly, Johnson et al reported better 
visualization of the prostate in approximately 45% of patients after HBB administration at 1T 
[5]. Roethke et al demonstrated a non-significant effect of HBB on the quality of T2W 
images in 70 patients, scanned at 3T without an ERC [6]. However, despite not reaching 
significance, they demonstrated an improvement for all image quality categories and a 
reduction in artefacts with HBB administration. Conversely, a study by Wagner et al did not 
demonstrate a significantly improved visualization of the prostate at 1.5T MRI using an 
endorectal coil (ERC), and argued the low position of the prostate, remote from the small 
bowel, reduced the effects of peristalsis [7]. However, an endorectal coil is not routinely 
used in most centres performing prostate MRI. The effect of DCE acquisition is likely to be 
more complicated, but the lower TR employed and k-space sampling strategy used will help 
reduce intra-acquisition motion artefact. Interestingly, our study shows that HBB has a 
significant effect on the anatomical but not on the functional sequences. The Echo planar 
imaging (EPI) readout of DWI typically samples all of k-space in one to two TR periods, 
dependent on the number of shots, which acts to reduce the effects of motion. DWI The 
timing of the DCE acquisition, approximately 30 mins post HBB injection, means the effects 
of HBB may well have worn off, negating any HBB-related differences between the groups. 
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There are a limited number of previously studies looking at the issue of rectal distension and 
prostate MRI quality. Lim et al [8] showed no improvement in the quality of DWI, T2W or 
DCE prostate images in a retrospective study of 28 patients receiving a cleansing enema 
prior to imaging. Despite showing a significant correlation of stool volume to motion 
artefact on T2 and the presence of less stool in the enema group, there was no significant 
difference to a control group with no enema. Of note however, only a minority of patients 
(16%) in the non-enema group had moderate or large amounts of stool, compared to 38.2% 
in our cohort. Another confounding factor may be the introduction of air post-enema, as the 
induced susceptibility artefact may have counteracted the effect of stool distension. 
Classical susceptibility artefact occurs at the interface of two substances which have 
different magnetic susceptibilities, in this case the interface of air within the rectum and the 
prostate. The echo planar readouts used within diffusion weighted imaging are particularly 
susceptible to magnetic field in-homogeneities which are prevalent at air tissue boundaries 
due to accumulated phase errors in the readout. 
 
2.2.7 Limitations 
The study has some limitations, including its retrospective nature. Future prospective 
studies would ideally allow paired analysis comparing patients pre- and post-HBB, for direct 
comparison. Cancer detection rates were not directly assessed as part of this study as the 
main purpose was to evaluate image quality, this could form the basis of future work, in 
order to better determine whether HBB administration and/or rectal distension have a 
clinical impact. 
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2.2.8 Conclusions 
In terms of patient preparation, these findings support the use of spasmolytic agents to 
improve T2 image quality and suggest measures to limit rectal loading will help to optimise 
DW image quality and limit motion artefact on T2 weighted-imaging. Clearly patient-related 
factors can be controlled and optimised.  
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2.3 The longitudinal effect of ejaculation on seminal vesicle fluid volume and whole 
prostate ADC as measured on prostate MRI 
 
2.3.1 Background 
A primary purpose of mpMRI remains staging of prostate cancer, and determining seminal 
vesicle (SV) involvement (T3b disease) has implications for risk stratification, management 
and long-term prognosis. Optimal assessment of T3b disease is thought to require maximal 
SV distension [9] and some centres recommend that patients refrain from ejaculation for 3 
days prior to MRI to achieve this [10, 11]. However, evidence for this practice is lacking, with 
only one prospective MRI study documenting SV volume change in relation to ejaculation, 
with a 41% mean reduction immediately post-ejaculation [12]. Scanning at this time point is 
not representative of a clinical list and it may be that fluid replacement occurs relatively 
rapidly. A normal volunteer study was therefore designed to prospectively investigate the 
longitudinal effect of ejaculatory abstinence on MRI measured seminal vesicle volume and 
whole prostate ADC over consecutive days [13]. 
 
2.3.2 Methods 
15 healthy male volunteers (mean age 35.9 years, range 27-53) were included in this 
prospective, institutional review board-approved study (CUH/15/YH/0570). MR imaging was 
performed on 4 consecutive days. The subjects were instructed to refrain from ejaculation 
for ≥3 days prior to first MRI, to perform ejaculation after scan 1 and prior to scan 2, then 
abstain from ejaculation until completion of the study. Scans 2, 3, and 4 were therefore 
performed 1-24, 48, and 72 hours post-ejaculation, respectively. 
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2.3.3 Magnetic Resonance Imaging  
MRI was performed on a 3T MR750 magnet (General Electric Healthcare, Waukesha, USA) 
using a 32-channel phased array cardiac coil. Sequences: high resolution axial T2 weighted 
fast recovery fast spin echo imaging, TR/TE 3663/102 ms field-of-view (FOV) 22x22 cm, 3/0 
mm slice thickness/gap, in-plane resolution 0.85x0.57 mm, and 3 signal averages; sagittal T2 
cube sequence, 1 mm slice thickness with no gap, in-plane resolution 1.0x0.8 mm. Axial DWI 
acquired as a dual spin-echo planar pulse sequence with TR/TE 3775/70ms, FOV 28×28 cm, 
resolution 2.2x2.2 mm, 6 signal averages and b-values of 150/750/1000/1400 s/mm2 with 
automated ADC maps generated. 
 
2.3.4 MR Segmentation 
Seminal vesicle (SV) and prostate volumes were calculated using whole volume 
segmentation on T2-weighted images using in-house software programmed in Matlab 
(Mathworks, MA, USA). Whole gland ADC measurements were acquired after outlining the 
prostate using the relevant T2-weighted axial sequence as an anatomical reference. Outlines 
were drawn in a random order, blinded to the timing pre or post-ejaculation. For SV volume, 
a separate calculation was made of fluid volume by excluding the wall volume which is 
expected to remain constant, but contributes proportionately more to the overall volume 
when the seminal vesicles are collapsed or under-filled. A thresholding method was applied 
and set to a fraction (f) of the maximum pixel intensity (Smax) calculated as the 95% 
percentile in the SV ROI intensity histogram. The maximum signal in the centre slice was 
found and the threshold set to S > (Smax  f), where the fraction f was set at 0.7 or 0.8 
(depending on the presence of motion-induced ‘blurring’); Figure 2.3. 
 
48 
 
 
Figure 2.3: Example of seminal vesicle volume change over time. Top row: Axial T2-weighted MR 
imaging performed at baseline (minimum 3 days post-ejaculation), and post ejaculation on days 1, 2 
and 3. Top row: subject 5 (aged 27) shows significant reduction in volume from a baseline of 9.7 cm3 
to 3.6 cm3 on day 1 and subsequently 4.7 cm3, 6.9 cm3 on days 2 and 3, respectively. Bottom row: 
Manual regions-of-interest (yellow) were drawn outlining SVs on all slices for segmentation. To 
remove the SV wall component, the maximum signal in the central outlined was identified and a 
threshold applied for inclusion of pixels >(Smax  f). 
 
 
2.3.5 Statistics 
A linear mixed effects model was fitted to the seminal vesicle fluid volume and whole 
prostate ADC observations. Each model included fixed effects for the time of the 
observation (baseline, day 1, day 2 or day 3) and random effects for each individual to 
account for correlation within individuals. A log transform was applied to the data to ensure 
homoscedastic error variance. Spearman’s correlation was performed to assess any 
relationships. Statistical analyses were performed using Stata®14 (StataCorp LP, Texas, USA). 
P-values of <0.05 were considered to be statistically significant.  
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2.4 Results 
All 15 volunteers completed each of the 4 scans at the appropriate time. For one subject, 
there was a technical failure of diffusion-weighted imaging on the day-1 scan and the results 
were excluded from the ADC analysis. 
 
2.4.1 Volume measurements 
The mean prostate volume measured on the final scan was 22.45 cm3 (median 23.28 cm3, 
range 13.04 - 31.21 cm3). There was no change in whole gland prostate volume between the 
4 studies, baseline: 22.46 cm3, day-1: 22.47 cm3, day-2: 22.53 cm3, and day-3: 22.45 cm3 (P = 
0.89 - 0.99). 
 
There was no significant difference in overall average volume of the right (6.35 cm3) and left 
(6.13 cm3) seminal vesicles, with difference ranging from 0.21 – 2.17 cm3; P = 0.50. As 
expected, there was no change in SV wall volume between the studies, baseline: 6.31 cm3, 
day-1: 6.61 cm3, day-2: 6.59 cm3, and day-3: 6.65 cm3; P = 0.38 - 0.49.  
 
The average seminal vesicle fluid volume on the final scan was 5.82 cm3 (median 5.25 cm3, 
range 2.1 - 14.52 cm3). There was a reduction in SV fluid volume in 13/15 subjects from 
baseline to day-1. SV fluid volume significantly reduced from an average of 6.45 cm3at 
baseline to 4.80 cm3at day-1 (25.6% reduction, P < 0.001) and to 5.28 cm3 at day-2 (18.1% 
reduction, P = 0.002). There was a significant increase in volume from 4.80 cm3at day-1 to 
5.82 cm3 at day-3 post-ejaculation (35.1% increase, P = 0.006); Figure 2.4, Table 2.1.  
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Figure2.4: Seminal vesicle fluid volumes between each of the 4 scans. Fluid volumes measured on 
T2-weighted images for all 15 normal volunteers at baseline and at 1, 2, and 3 days post-ejaculation. 
 
 
 
 
 
Comparison Absolute  
change (cm3) 
 
Percentage  
change (%) 
p-value 
Baseline vs day 1 -1.65 
(1.85) 
-25.1 
(19.9) 
<0.001* 
Baseline vs day 2 -1.18 
(2.5) 
-19.5 
(29.3) 
0.002* 
Baseline vs day 3 -0.63 
(1.86) 
-9.77 
(38.0) 
0.38 
Day 1 vs Day 2 0.48 
(1.81) 
10.0 
(30.2) 
0.59 
Day 1 vs Day 3 1.02 
(1.33) 
21.3 
(43.3) 
<0.006* 
Day 2 vs Day 3 0.55 
(1.41) 
10.2 
(34.0) 
0.022* 
 
Table 2.2: Comparison of mean Seminal Vesicle fluid volumes between studies. Standard deviation 
in parentheses; * P < 0.05, denoting significance. 
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2.4.2 Quantitative whole gland ADC measurements 
There was a reduction ADC value in 10 of 14 subjects from baseline to day-1, with a 
significant mean reduction from 1.105 x 10-3 mm2/s at baseline to 1.056 x 10-3 mm2/s at day-
2 (4.3% reduction, P = 0.009). There was a general trend for ADC values to subsequently 
increase from day 2 to 3, but this was not significant (Figure 2.5, Table 2.2). 
 
 
 
 
 
 
Figure 2.5: Whole-gland prostate ADC values between each of the 4 scans. ADC values for 14 
normal volunteers at baseline and at 1, 2, and 3 days post-ejaculation. 
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Comparison Absolute change  
(10-3 mm2/s) 
 
Percentage  
change (%) 
p-value 
Baseline vs day 1 -0.049 
(0.078) 
-4.29 
(6.97) 
0.009* 
Baseline vs day 2 -0.023 
(0.054) 
-2.06 
(4.68) 
0.20 
Baseline vs day 3 -0.031 
(0.054) 
-2.66 
(4.77) 
0.10 
Day 1 vs Day 2 0.026 
(0.059) 
2.67 
(6.44) 
0.15 
Day 1 vs Day 3 0.019 
(0.082) 
2.19 
(8.84) 
0.28 
Day 2 vs Day 3 -0.007 
(0.058) 
-0.77 
(5.69) 
0.71 
 
Table 2.3: Comparison of mean whole prostate ADC values between scans. Standard deviation in 
parentheses; * P < 0.05, denoting significance. 
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2.5 Discussion 
This study demonstrates the longitudinal MR measurements of seminal vesicle fluid volume 
following ejaculatory abstinence for the first time. There was a significant reduction in SV 
fluid volume within a day of ejaculation and maintained at day-2. This was confirmed by an 
increase in volume on successive days post-ejaculation, with significantly higher volumes 
observed at day-3 compared to day-1 and 2, suggesting a minimum 3-day period of 
abstinence is required for maximal SV distension. A similar effect was seen for ADC values, 
with a significant reduction in values at day-1 post-ejaculation. 
 
Although many centres recommend abstinence from ejaculation prior to prostate MRI, 
evidence to support this practice is lacking. The rationale may be based on practice for the 
investigation of male fertility, where abstinence of 2-7 days is recommended for sperm 
analysis [14]. Semen volume (by 24%) and sperm density are reduced in men with 
abstinence of only 1 day compared to ≥4 days [15, 16]. It should be noted that although 
seminal vesicle fluid makes up 60-85% of the ejaculate [17], there are also contributions 
from the prostate gland (15-30%), testis (<5%) and bulbourethral glands (1-5%), thus 
ejaculate volume alone may not provide an accurate indication of changes in SV volume. 
Early work using vesiculography [18] and ultrasound [19, 20] and subsequently confirmed by 
a more recent MRI study [6] showed 30-40% reductions in seminal vesicle volume 
immediately post-ejaculation. However, these studies are not representative of an out-
patient MR patient population. A more recent study demonstrated lower SV volumes in 
patients imaged less than 3 days post last ejaculation, compared to more than 3 days [21]. 
This study only looked at the binary cut-off of 3-days and was additionally limited by use of 
SV planimetry measurements rather than image-segmentation volumetry. Furthermore, the 
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same patients were not directly compared, and inter-patient variation, in which SV length 
may vary up to 11-fold [22], may therefore have affected their results. 
 
A significant reduction was demonstrated in whole prostate ADC measurements within 24 
hours of ejaculation, and a non-significant increase in ADC was seen between days 2 and 3. 
This is consistent with earlier work in the immediate post-ejaculatory phase [12]. ADC 
reduces with increasing Gleason grade [23, 24], which partly relates to loss of fluid in the 
glandular lumen [25]; higher grade tumours also have also been shown to have a reduced 
luminal space [26]. The prostate gland contributes a small amount of fluid to the ejaculate 
[17] and although we did not demonstrate any appreciable change in prostate volume 
between studies, this fluid loss may be sufficient to have a dehydrating effect on the gland 
fluid, and thus reduce the ADC value. The effect of ejaculatory time on prostate ADC values 
is potentially of more clinical significance than the effect on SV volume, as this may affect 
lesion conspicuity and assessment, particularly in the PZ where DWI is the key mpMRI 
sequence. Standardization of patient preparation prior to prostate MRI may help to reduce 
inter-patient variations in ADC measurements and improve quantitative analysis, as well as 
addressing intra-patient variation in the context of follow-up in patients on active 
surveillance programs. Morgan et al [27] suggested that in patients on active surveillance, a 
reduction in the whole-gland ADC of >10% was associated with progression to radical 
treatment and that non-progressors also showed a less marked decrease in ADC. However, 
in a small cohort of prostate cancer patients, Fedorov A, et al [28] showed that ADC 
repeatability varied up to 40% for small lesions that would be appropriate for AS, which 
would call into question the use of the parameters quantifiably. 
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We did not look at the question of dynamic contrast-enhanced MRI, as multiple repeat 
Gadolinium injections in normal volunteers could not be justified, however, it is possible 
that this may also be affected by post-ejaculatory status, with a previous ultrasound study 
showing ejaculation affected the clinical assessment of prostatitis by increasing prostatic 
blood flow for at least 24 hours [29].  
 
2.5.1 Limitations 
There were several limitations to the study. The study population was a small cohort of 
healthy volunteers who were of a younger age than typical patients with prostate cancer. It 
has been demonstrated that SV volume in healthy patients decreases after the age of 60 
years [30]; however, this may be partially off-set by an increase in volume in patients with 
BPH [31]. Although these results should hold regardless of baseline volume, it is unclear 
whether they would be affected by an underlying disease process, or indeed whether 
diagnostic interpretation would be hindered. It has been suggested that the replenishment 
of seminal fluid in younger patients is more rapid and therefore the effects of abstinence 
may be less apparent [21]; while there is no direct evidence for this, it would suggest that 
the results demonstrated here in young volunteers would be more marked if repeated in an 
older age group, and further strengthens the argument for a period of abstinence prior to 
scanning. Larger studies in patients with prostate cancer, ideally incorporating age-
appropriate healthy controls, would serve to overcome these limitations and would also 
help address whether the observed variation in ADC values affects lesion conspicuity and 
detection. 
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2.5.2 Conclusions 
In conclusion, the longitudinal effect of ejaculation on seminal vesicle volume as measured 
by MR imaging has been demonstrated in a young cohort without prostate cancer. Seminal 
vesicle volume is significantly reduced at days 1 and 2 post-ejaculation and increases to day-
3. Whole-gland prostate ADC values also significantly reduced at day-1 post-ejaculation. The 
results require confirmation in an age-appropriate cohort, but support the rationale for a 3-
day period of abstinence from ejaculation prior to diagnostic prostate MRI. 
 
2.6 Chapter Summary 
It is apparent that preparation and patient-related factors can affect the quality of images 
and attempts should therefore be made to control these in order to optimise the MRI study 
and outcomes. The effect of ejaculatory abstinence on whole-gland ADC is potentially more 
clinically significant than SV volume as this may affect lesion conspicuity and detection, 
whilst T3b involvement can be assessed by other secondary signs such as asymmetry or 
bulging and focal areas of enhancement and/or restricted diffusion. However, further 
testing of lesion detection is needed in the clinical MRI setting. A local (unpublished) 
questionnaire study (ethics: CUH/16/WM/0253) of 185 patients undergoing prostate MRI 
indicated that only 22/185 (11.9%) of patients had ejaculated within the preceding 24 hours, 
with the majority (113/185; 61.1%) observing an ejaculatory free period of ≥72 hours. 
Therefore, even if ADC is affected within one day of ejaculation this may be less of a clinical 
issue in this patient context, with the majority (almost 90%) having not ejaculated within 
this period, even without any prior instruction.     
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Chapter 3: Evaluation of Magnetization Transfer and Diffusion Kurtosis MR imaging for 
prostate cancer detection in a re-biopsy population 
 
3.1 Introduction 
Having described the utility but limitations of standard clinical sequences used in mpMRI of 
the prostate, this chapter looks at the potential use of further functional sequences to aid 
cancer detection. The most recent version of the PI-RADS guidelines strongly supports the 
continued development of novel sequences, including diffusion tensor (DTI), diffusional 
kurtosis imaging (DKI), multiple b-value assessment of fractional ADC, and intravoxel 
incoherent motion (IVIM) [1]. In this study diffusion kurtosis imaging (DKI) and 
magnetization transfer imaging (MTI), two novel MR sequences that do not require 
administration of any exogenous contrast agents were assessed. 
 
Definitive pre-treatment diagnosis of prostate cancer still relies on the results of systematic 
transrectal ultrasound (TRUS) guided biopsies of the prostate, the limitations of which have 
already been described. In patients with an initial negative biopsy but continued clinical 
suspicion of prostate cancer, national guidelines in the UK recommend further assessment 
to exclude or confirm the presence of tumour [2]. Additionally, TRUS-biopsy may misclassify 
lesions as low grade due to sampling error, necessitating a repeat biopsy. Prostatic biopsy 
using MR targeting in such patients has been shown to improve pre-treatment risk 
stratification by reducing sampling error [3]. This re-biopsy population of patients was 
identified as potentially benefiting from improved MRI sequences, and formed the study 
cohort. The route of repeat biopsy chosen was fused US-MRI targeted biopsy via a 
transperineal approach.  
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3.1.1 Transperineal prostatic biopsy 
Biopsies performed using the transperineal approach are often considered in re-biopsy 
patients and offer certain advantages over standard TRUS-guided biopsy. Transperineal 
ultrasound (TPUS) guided biopsy utilizes a sterile technique, reducing the risk of biopsy 
associated infection, and also has an increased ability to detect cancers located in the 
anterior and apical regions of the prostate, two areas that are frequently under sampled 
through TRUS biopsy. Factors limiting its use include increased time, limited availability of 
equipment, and the need for general anaesthesia [4]. Further improvements in pre-biopsy 
MR imaging by incorporation of newer and more novel techniques could enable more 
accurate targeting of TPUS biopsy, minimising the cores acquired and thus help to limit 
some of the disadvantages of the technique by reducing morbidity, surgical time, and the 
cost of the procedure. In theory initial TRUS biopsy could be replaced by TPUS in certain 
patients with suspicion for anterior or apical tumours, reducing the overall rate of negative 
biopsies. 
  
3.1.2 Diffusion Kurtosis Imaging 
Conventional diffusion-weighted imaging quantifies water diffusion within tissue by 
acquiring a number of b-value images at different gradient strengths and then applying a 
mono-exponential mathematical model to the signal decay in order to produce an apparent 
diffusion coefficient (ADC) map. The mono-exponential model assumes that the diffusion of 
water molecules follows a Gaussian (normal) distribution. However, while this assumption 
may hold for pure liquids, it is not true for complex biological tissues with compartments 
and barriers to diffusion [5]. At lower b-values with short measurement times, most 
molecules will not have enough time to reach cell membranes or other boundaries, and a 
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mono-exponential model may suffice. However, at higher b-values, with increasing diffusion 
time, a higher proportion of molecules strike the boundaries, resulting in a deviation of 
diffusion from normal Gaussian behaviour [5, 6]; Figure 3.1. Diffusion kurtosis imaging (DKI) 
is a form of diffusion-weighted imaging that exploits the degree to which water diffusion in 
tissues differs from what would be expected under a normal (Gaussian) distribution of 
displacements [7]. 
 
 
 
Figure 3.1. Deviation of the DWI signal from a mono-exponential model. At low b-values intravoxel 
incoherent motion (IVIM) perfusion in capillaries caused a deviation (green), at high b-values 
Kurtosis produces a deviation of the graph in the opposite direction, resulting in lower than 
expected apparent diffusion coefficient values (yellow). 
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Theoretically, kurtosis values may quantify the variability in tissue structure within the 
region of interest, providing a measurement of tissue heterogeneity, which may be useful 
for assessing structural abnormalities in pathologic regions. DKI measures two parameters, 
the apparent diffusivity Dapp quantifies the exponential component of signal decay and is 
similar to the Apparent Diffusion Coefficient (ADC) in the standard monoexponential model. 
The apparent kurtosis Kapp measures the first-order deviation from monoexponential decay 
and is thus a simple measurement of the deviation from a Gaussian distribution of 
displacements. Previous retrospective studies have suggested a possible correlation 
between Kapp and prostate cancer aggressiveness [8, 9], although a recent large 
retrospective study showed that despite good independent results for DKI, no added value 
was observed over standard DWI sequences [10].  
 
3.1.3 Magnetization Transfer Imaging  
Another potential functional sequence is magnetization transfer imaging (MTI), which 
images the interaction of free and bound water molecules. MTI quantifies the transfer of 
nuclear spin polarisation between the “bound” and “free” pool of water within tissues. The 
“free” pool consists of relatively mobile protons, and provides the majority of the visible MR 
signal. The “bound” pool incorporates both macromolecules and the “hydration layer” of 
water molecules bound to their charged surface by hydrogen bounds. The protons 
associated with macromolecules are relatively immobile, as such their T2 relaxation times 
are very short (≈10 - 15 μs) and their decay time too rapid for an MR signal to be detected 
[11]. However, the hydration layer of water is able to interact with the “free” pool on its 
outer surface, and is able to modulate the relaxation properties of free water via dipole-
dipole interactions, thereby affecting its MR signal.  
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This effect is exploited in MTI, where an off-resonance radiofrequency pulse is applied to 
saturate the hydration layer of the bound pool, with this saturation then being transferred 
(magnetization transfer) to the water protons in the free pool. Depending on the exchange 
rate between the two pools, the free pool of protons will become partially saturated and, if 
subsequently imaged, its signal will be reduced. The change in signal intensity pre- and post-
application of the MT pulse for a given voxel can be defined and computed as the 
magnetization transfer ratio (MTR), according to the equation:  
 
MTR (%) = 
 MToff − MTon
MToff
 𝑥 100                                     
Where MToff represents the baseline reference signal intensity and MTon represents the 
intensity following the saturation pulse  
 
MTR relates to the organization of macromolecular protons in the tissue and is thought to 
be an indicator of the structural integrity of tissues and the microstructural changes induced 
by pathological processes [12]. MTR has been shown to increase in malignancy, with 
changes thought to derive from a combination of abnormal cell membrane structures or 
changes in cell number or size [13, 14]. Preliminary work in prostate cancer demonstrated 
higher MTR within the whole PZ in patients with known prostate cancer, compared to 
normal appearing tissue in biopsy-negative patients [15]. These results supported earlier 
work in MTR, where a subset of 22 patients with localised prostate cancer demonstrated 
higher MTR in cancer compared to controls, with a reduction in values following hormone 
therapy [16].  
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Advanced functional imaging with DKI and MTI may provide insight into the tissue structure 
of prostate cancer and help us to better understand the complicated micro-environment of 
tumours. We therefore aimed to evaluate whether the addition of these two novel MR 
quantification parameters to standard MRI sequences could aid prostate cancer detection in 
a TPUS re-biopsy population.  
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3.2 Methods 
 
3.2.1 Patient population 
30 patients with a clinical suspicion of undiagnosed prostate cancer were prospectively 
enrolled into this institutional review board and ethics committee approved single-
institution study (CUH/13/EE/0100) [17]. Participants were recruited between November 
2013 and June 2016, with written informed consent obtained in all cases. Inclusion criteria 
included negative biopsy with continued suspicion of prostate cancer (for example, high 
and/or rising PSA levels) and a suspicious lesion on MRI (n = 24), or a previous diagnosis of 
low-grade cancer with MRI suspicious for a new lesion in a remote location of the gland (n = 
6). Patients subsequently underwent an MR-TRUS fusion template transperineal biopsy, 
including target cores from any MRI suspicious lesion/s. 
 
3.2.2 MR Imaging 
All patients underwent 3T MRI (MR 750, GE Healthcare, Waukesha, WI, USA) using a 32-
channel phased-array body coil. The protocol included three-plane localizer images followed 
by multiplanar T2-weighted fast recovery fast spin-echo (FSE) images of the prostate and 
axial T1-weighted FSE images of the pelvis. The high resolution T2-weighted axial 
parameters were: TE 99-106ms; TR 3000-5000ms; field-of-view (FOV) 22x22 cm; acquisition 
matrix 384x288 (giving in plane resolution 0.6 x 0.8 mm); 3 signal averages; no-phase-wrap; 
slice thickness 3.0 mm/gap 1.0 mm; echo-train length (ETL) 16; receiver bandwidth ±50Hz.  
 
Standard clinical axial DWI was performed using both single spin-echo and dual spin-echo 
echo-planar imaging (EPI) pulse sequences: TE 67-72ms (single SE) or 90ms (dual SE); TR 
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4000ms; FOV 28×28 cm; acquisition matrix 144x144 (giving resolution 1.9 x 1.9mm2); slice 
thickness 4mm (no gap); receiver bandwidth ±111 kHz; parallel imaging (ASSET) factor 2; 8 
signal averages; b values of 100 and 1000 s/mm2, with ADC maps automatically generated 
by the scanner software, using monoexponential fitting. Additional data was acquired with 
b-value of 1400 s/mm2 with the same acquisition parameters except: acquisition matrix 
128x128 (resolution 2.2x2.2 mm2) and a slightly increased TE of 70-75ms. 
 
DKI was performed as a single-shot dual-spin-echo EPI pulse sequence: TE/TR = 94/6000 ms; 
6 signal averages; parallel imaging (ASSET) factor 2; FOV 28 x 28 cm2; acquisition matrix 
128x96 (giving resolution 2.2x2.9 mm2); slice thickness 3.6 mm/gap 0.4 mm; b-values of 150, 
450, 800, 1150, 1500 s/mm2; receiver bandwidth ±111 kHz. The DKI model used second-
order approximation to the exponential dependence of DWI signal S with b-value (b): 
 
 
Where S0 is the signal when b = 0 s/mm
2 
 
Magnetization transfer imaging volumes covering the prostate were acquired with two 3D 
spoiled gradient recalled-echo acquisitions (SPGR) which were acquired with- and without 
an MT saturation pulse with the following scan parameters: TR=24ms, TE= 2.4ms, flip angle= 
5°, acquisition matrix= 256 x 160 and FOV=22cm, slices=22 with slice thickness matched to 
the T2 axial series. The saturation pulse consisted of a 400° Fermi shape pulse, of 10ms 
duration and 800 Hz bandwidth at 2.5 kHz off-resonance frequency. DKI (Dapp and Kapp) and 
magnetization transfer ratio (MTR) parameter maps were calculated offline using custom 
software written in Matlab (Mathworks, MA, USA). 
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DCE images were acquired as an axial 3D fast-spoiled gradient echo (GRE) sequence: TR/TE 
5.4/2.4ms; flip angle 17; FOV 22x22 cm2; acquisition matrix 192x160x22-26; slice thickness 
4mm; 0.75 Nex; receiver bandwidth ± 31 kHz; 85–100 dynamic phases with temporal 
resolution 7s. Gadobutrol (Gadovist, Schering AG) was injected i.v. as a bolus, via a power 
injector (rate 3 mL/s, dose 0.1 mmol/kg) followed by a 25 mL saline flush, with a total scan 
duration of approximately 10 minutes. 
 
3.2.3 Image analysis 
The MRIs were prospectively read by 1 of 2 uro-radiologists with more than 4 years’ 
experience of clinical prostate MRI reporting at a high-volume tertiary referral centre. 
Images were analysed according to the Prostate Imaging-Reporting and Data System (PI-
RADS) version 1 criteria [18] prior to February 2015 and subsequently using criteria as 
described in PI-RADS version 2 [4]. In all cases, interpretation of the images was based on 
the following Likert scoring scale for tumour probability: 1 = very low (clinically significant 
cancer is highly unlikely to be present), 2 = low (clinically significant cancer is unlikely to be 
present), 3 = intermediate (the presence of clinically significant cancer is equivocal), 4 = high 
(clinically significant cancer is likely to be present), 5 = very high (clinically significant cancer 
is highly likely to be present). Although similar to the scoring system subsequently adopted 
in PI-RADS version 2, a size criterion was not used to determine lesion probability. Thus 
whilst category 1, 2, 3 and 5 are equivalent, PI-RADS category 4 lesions will differ and, 
depending on size or lesion conspicuity, may be categorised as scores 3, 4 or 5 using the 
Likert system. The DKI and MTR values did not inform biopsy decision making. For the 
purposes of the study, a positive MRI lesion was defined as a score of ≥3; targets were 
prospectively drawn on the Biopsee™ platform, using T2W as primary, and ADC as 
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secondary source images.  
 
3.2.4 Biopsy procedure 
The Biopsee™ MRI/TRUS-fusion biopsy system biopsy system v.1 or v.2 (Medcom, 
Darmstadt, Germany) was used for all biopsies. It includes computer hardware and software 
for image fusion and an ultrasound machine. A transrectal BK Medical (Peabody, 
Massachusetts, USA) FlexFocus™ ultrasound probe was sited, the biplanar probe is fixed on 
a stepping unit and sagittal images of the prostate were aligned with MR images using 
fusion software. All patients underwent systematic transperineal biopsies according to the 
Ginsburg protocol, using a spring-loaded biopsy gun and 18G needle via a brachytherapy 
template grid [19]; Figure 3.2. In all cases, 2 biopsy cores were taken from each lesion(s) 
first, with 24 background systematic biopsies subsequently acquired. All procedures were 
performed by 1 of 3 urologists with several years’ experience of transperineal biopsy. 
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Figure 3.2. Ginsburg Transperineal biopsy protocol. Background areas of the prostate gland are 
systematically sampled according to the above template, using a transperineal brachytherapy grid. 
 
 
3.2.5 Histopathology  
All biopsies were graded with a Gleason score following the ISUP 2005 recommendations 
[20] by a specialist uropathologist. The final histology result from this assessment was used 
as data for the study. 
 
3.2.6 Retrospective analysis  
Prospectively defined target outlines are stored on the local clinical picture archiving and 
communication system (PACS, GE Healthcare) as part of the standard clinical workflow. A 
fellowship-trained radiologist with 7 years of clinical prostate MR reporting experience 
reviewed the original outlines and re-drew freehand regions-of-interest (ROIs) 
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corresponding to the target outline on T2-weighted axial images and avoiding inclusion of 
the urethra or extra-prostatic tissue where relevant, using in-house software programmed 
with Matlab (MathWorks, Natick, MA). Additional ROIs were drawn in regions of benign PZ 
and TZ. Benign ROIs were defined as “normal appearing” on standard mpMRI sequences, on 
the side contralateral to the target, and with corresponding negative cores on biopsy, drawn 
where possible over 3 consecutive MR slices, with a minimum volume of 0.5 cm3. All ROIs 
were stored and secondarily transposed onto the ADC, DKI, and MTR maps; in cases of 
significant distortion, the ROIs were adjusted to allow for this, using the T2-weighted images 
for reference. DKI (Dapp and Kapp) and magnetization transfer ratio (MTR) parameter maps 
were calculated offline using custom software written in Matlab. For DKI, the noise-only 
images were used to reduce and partially compensate for noise-floor bias which could 
otherwise artificially enhance the kurtosis measurement [10]. A small proportion of DKI fit-
failure pixels were excluded. The mean ROI values of ADC, Dapp and Kapp, and MTR maps 
were used for analysis. 
 
3.2.7 Statistical analysis  
Medians and ranges were used to summarize continuous variables. Wilcoxon signed-rank 
test was performed to assess the relationships between parameters and benign tissue 
versus tumour tissue and between tumour grades, for both the PZ and TZ. Receiver 
operating characteristic (ROC) analyses were used to assess the diagnostic utility of the 
metrics, alone and in combination, for the detecting tumour and for discriminating different 
Gleason grades of tumour. An optimal threshold was determined for each metric for 
discriminating tumour from benign tissue. Pearson’s correlation was performed to assess 
the relationship between the different metrics assessed, where -1.0 to -0.75 is considered a 
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strong negative association, -0.75 to -0.5 moderate negative, -0.5 to -0.25 weak negative, -
0.25 to +0.25 no linear association, +0.25 to +0.5 a weak positive association, +0.5 to +0.75 
moderate positive, and +0.75 to +1.0 a strong positive association. All statistical analysis was 
performed in R (version 3.1.1, The R Foundation for Statistical Computing, Vienna, Austria); 
p < 0.05 was considered statistically significant. 
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3.3 Results 
Thirty patients were included in the study group, with a median age of 65.5 years (mean 
64.7, range 50 - 76 years) and a median pre-biopsy PSA level of 7.67 ng/mL (mean 8.9, 
interquartile range 6.12 - 11.98 ng/mL). The median time from MRI to biopsy was 26 days 
(mean 37.5, IQR: 7.25 - 48.25 days). 26 patients had a least 1 previous biopsy, with interval 
from most recent biopsy to MRI at least 3 months (median 13 months, range 3 - 114 
months, interquartile range 4 - 26 months). 
 
Prostate cancer was detected in 24/30 patients including targeted and background cores 
and in 20 patients within at least 1 target core. In the 4 patients with only background cores 
positive all had Gleason score (GS) 3+3 in 1-5% of 1 core only. The remaining 20 patients had 
26 separate MRI lesions with positive target cores (4 patients with 2 targets, 1 with 3), of 
which 13 were in the peripheral zone (PZ) and 13 in the transition zone (TZ). The final 
pathology of the 26 targets was GS 3+3 (n=8), 3+4 (n=12), 3+5 (n=1), 4+3 (n=2), and ≥4+4 
(n=3); Table 3.1. 
 
 
Gleason 
Grade 
Overall Peripheral 
Zone 
Transition 
Zone 
Benign 10 3 7 
3+3 8 4 4 
3+4 12 8 4 
3+5 1 0 1 
4+3 2 0 2 
4+4 1 1 0 
4+5 2 0 2 
Table 3.1. Target biopsy outcomes for MRI defined lesions 
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Mean tumour ADC (PZ: 0.902, TZ: 0.845 x 10-3mm2s-1) and Dapp (PZ: 1.167, TZ: 0.951 x 10
-
3mm2s-1) values were significantly lower than normal PZ (ADC 1.579, Dapp 2.221 x 10
-3mm2s-
1) and benign TZ (ADC 1.270, Dapp 1.808 x 10
-3mm2s-1); Figure 3.3. Conversely, mean Kapp and 
MTR values were significantly higher for PZ tumour (716, 25.0%, respectively) and TZ 
tumour (871, 30.0%, respectively) compared to normal PZ (507, 20.0%, respectively) and TZ 
(615, 26.9%, respectively). Normal TZ had lower ADC and Dapp and higher Kapp and MTR than 
normal PZ tissue, with cystic BPH demonstrating higher ADC and Dapp and lower Kapp and 
MTR compared to normal TZ. For all parameters there was a significant difference between 
both normal and tumour tissue and cystic BPH and normal TZ (p = 0.005 - <0.001); Table 3.2.  
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Figure 3.3. Raw b-value image data and fitting of the DKI model.  
65 year old man, PSA 17.15 ng/ml. A: T2WI shows a lesion in the right base PZ (arrow), target biopsy 
Gleason 4+4 tumour in 50% of both cores. B: ADC map shows restricted diffusion (0.894 x 10-3 
mm2s-1). C: Kapp map shows average tumour value of 697.6. D: Signal intensity decay plotted against 
b-value for normal (red) and tumour (blue) using a diffusion kurtosis compared to a mono-
exponential (dashed line) model, showing improved fitting of the data at the higher b-values. 
Bottom row: source b-values images acquired (left to right) at 150, 450, 800, 1150, and 1500 s/mm2.  
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Parameter Normal Tissue Tumour Target Cystic BPH p-value 
(normal vs 
tumour) 
p-value 
(normal vs 
cystic BPH) 
 
ADC (x 10-3 mm2s-1) 
 Peripheral Zone 1.579 
[1.363 – 1.794] 
0.902 
[0.869 – 0.974] 
N/A <0.001 N/A 
 Transition Zone 1.270  
[1.244 – 1.355] 
0.845  
[0.813 – 0.885] 
1.955  
[1.669 – 2.031] 
<0.001 <0.001 
 
Dapp (x 10
-3 mm2s-1) 
 Peripheral Zone 2.221 
[2.039 – 2.446] 
1.167 
[0.910 – 1.366] 
N/A <0.001 N/A 
 Transition Zone 1.808 
[1.712 – 1.895] 
0.951 
[0.853 – 1.062]  
2.152 
[2.113 – 2.258] 
<0.001 <0.001 
 
Kapp (unitless) 
 Peripheral Zone 507 
[426-550] 
716 
[621-869] 
N/A 0.004 N/A 
 Transition Zone 615 
[548 - 653] 
871 
[663 - 1034] 
374 
[303 - 501] 
0.004 0.001 
 
MTR (%) 
 Peripheral Zone 20.0 
[15.5 – 22.9] 
25.0 
[24.0 – 28.1] 
N/A <0.001 N/A 
 Transition Zone 26.9 
[23.5 - 28.0] 
30.0 
[28.2 - 32.0] 
15.2 
[6.9 - 21.3] 
0.005 <0.001 
 
Table 3.2. Target biopsy outcomes for MRI defined lesions and contralateral normal (benign) 
tissue. Mean values listed, Interquartile range in parentheses 
 
 
 
ADC was able to distinguish any Gleason-grade tumour from benign tissue with sensitivity 
and specificity of 92.3% and 100% in the PZ and 100% and 100%, respectively in the TZ. Kapp 
differentiated tumour in the PZ with 76.9% sensitivity and 83.3% specificity and 69.2% and 
100%, respectively in the TZ. MTR distinguished tumour from benign tissue with sensitivity 
and specificity of 76.9% and 86.7% in the PZ and 76.9% and 76.7%, respectively in the TZ; 
Figures 3.4 – 3.5. Tables 3.3 demonstrates the diagnostic utility of the metrics, with receiver 
operating characteristic (ROC) area under the curve (AUC) values ranging from 0.767 to 
1.000 for separating tumour from benign tissue (Figure 3.6). 
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Figure 3.4. Peripheral zone target lesion. 64 year old with PSA of 6.5 ng/ml. Top row, clinical mpMRI 
sequences: T2w image (A), early time point DCE image (B) and b=1400 s/mm2 diffusion-weighted 
image (C). Bottom row, assessed sequences: ADC map, value 0.902 x 10-3 mm2s-1 (D), Kapp, value 
867.2 (E) and MTR, value 27.5% (F). The target in the right base PZ posteriorly (arrows) was 
prospectively defined. Note calcification in the left base TZ (* in A) with corresponding artefact on all 
other sequences. Target biopsy: 3+4=7 (35% pattern 4) in 60% cores. 
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Figure 3.5. Peripheral and transition zone target lesions. 69 year old with PSA of 12.31 ng/ml. Top 
row, clinical mpMRI sequences: T2w image (A), early time point DCE image (B) and b=1400 s/mm2 
diffusion-weighted image (C). Bottom row, assessed sequences: (D): ADC map (values: PZ lesion 
1.037 x 10-3 mm2s-1, TZ lesion 0.885 x 10-3 mm2s-1), (E): Kapp (values PZ lesion 715.6, TZ lesion 518.5) 
and (F): MTR (values PZ lesion 24.4%, TZ lesion 31.7%). Targets prospectively drawn in the anterior 
mid gland TZ (outlines) and right mid PZ posteriorly (arrows). Both lesions positive on Kapp and MTR 
maps, note clear zonal differentiation seen on MTR maps. Target biopsy, PZ lesion: Gleason 3+4 in 
2/2 cores 50%, up to 8 mm; TZ lesion: Gleason 3+3 in 2/2 cores 50%, up to 4 mm.  
 
 
 Cut-Off AUC Sensitivity (%) Specificity (%) 
 
ADC x 10-3 mm2s-1 
 Transition Zone 1.076 1.000 100.0 100.0 
 Peripheral Zone 1.037 0.979 92.3 100.0 
 
Dapp x 10
-3 mm2s-1 
 Transition Zone 1.524 1.000 100.0 100.0 
 Peripheral Zone 1.481 0.990 100.0 96.7 
 
Kapp (Unitless) 
 Transition Zone 819.9 0.772 69.2 100.0 
 Peripheral Zone 621.2 0.772 76.9 83.3 
 
MTR (%) 
 Transition Zone 28.2 0.767 76.9 76.7 
 Peripheral Zone 24.0 0.828 76.9 86.7 
 
Table 3.3. Diagnostic utility of each respective metric in separating normal tissue versus tumours 
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Figure 3.6. Receiver operating characteristic curves of the performance of ADC, Dapp, Kapp, and MTR 
for differentiating benign tissue and tumour in the peripheral zone (top) and transition zone 
(bottom). 
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The ability of the parameters to distinguish lower grade (Gleason 3+3) from higher grade 
(Gleason ≥3+4) was assessed. The different values derived for normal and tumour tissue for 
all metrics in the PZ and TZ necessitated a separate analysis by tissue type. The Gleason 3+3 
group included 4 PZ and 4 TZ tumours, the GS ≥3+4 included 9 PZ and 9 TZ tumours. All 
measured parameters were poor at separating lower and higher grade disease for both PZ 
(p = 0.414 - 0.825) and TZ (p = 0.148 - 0.825); Figures 3.7 and 3.8 and Table 3.4. 
 
 
 
 
Figure 3.7. Box and whisker plots for distinguishing Gleason (GS) 3+3 from GS ≥3+4 tumours for 
ADC (a), Dapp (B), Kapp (C) and MTR (D). Top and bottom of boxes represent 25
th and 75th percentiles 
of data, line in boxes represents the median value and bars representing data within 1.5 times 
interquartile range. Circles denote outliers. 
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Figure 3.8. Receiver operating characteristic curves of the performance of ADC, Dapp, Kapp, and MTR 
for differentiating lower grade (Gleason 3+3) from higher grade (Gleason ≥3+4) tumour in the 
peripheral zone (top) and transition zone (bottom). 
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 Gleason 3+3 
 
Gleason ≥3+4 
 
p-value 
 
  
Peripheral Zone 
 
n = 4 
 
n = 9 
 
 ADC x 10-3 mm2s-1 905 
[860 - 949] 
902 
[893 - 1036] 
0.711 
 Dapp x 10
-3 mm2s-1 1275 
[1047 - 1463] 
1167 
[740 - 1196] 
0.414 
 Kapp (Unitless) 759 
[643 - 902] 
716 
[480 - 867] 
0.711 
 MTR (%) 26.1 
[23.4 - 28.4] 
25.0 
[24.0 - 27.5] 
0.825 
  
Transition Zone 
 
n = 4 
 
n = 9 
 
 ADC x 10-3 mm2s-1 881 
[864 - 887] 
830 
[799 - 884] 
0.414 
 Dapp x 10
-3 mm2s-1 926 
[889 - 979] 
1006 
[745 - 1083] 
0.825 
 Kapp (Unitless) 695 
[508 - 924] 
975 
[820 - 1035] 
0.414 
 MTR (%) 31.9 
[31.3 - 32.2] 
29.6 
[26.3 - 31.5] 
0.148 
 
Table 3.4. Ability of metrics to distinguish lower grade (Gleason 3+3) from higher grade (Gleason 
≥3+4) tumours. Mean values listed, interquartile range in parentheses 
 
 
 
ADC showed a strong overall correlation to Dapp (r = -0.862), as expected. ADC showed 
moderate inverse correlation to MTR (r = -0.618) and an inverse correlation to Kapp (r= -
0.767) in normal tissue, with a weak positive correlation in tumour tissue (r= -0.459 and -
0.444, respectively); details are given in Table 3.5. MTR showed a moderate correlation to 
both Kapp (r=0.570) and Dapp (r=-0.537) in normal tissue, but conversely showed no 
correlation to Kapp (r=0.141) and Dapp (r=-0.024) in tumour tissue (Figure 3.9 and 3.10). 
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Comparators Tumour Tissue  
(TZ + PZ) 
Normal Tissue  
(TZ + PZ) 
Normal + Tumour 
Tissue (TZ + PZ) 
ADC vs Kapp -0.444 -0.767 -0.641 
ADC vs Dapp -0.041 -0.790 0.862 
ADC vs MTR -0.459 -0.618 -0.633 
Kapp vs Dapp 0.646 -0.532 -0.359 
Kapp vs MTR 0.141 0.570 0.429 
Dapp vs MTR -0.024 -0.537 -0.531 
 
Table 3.5. Correlation between assessed metrics (Pearson’s Rho) 
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Figure 3.9. Correlation plots between assessed MTR and Dapp. Top: MTR compared to Dapp in normal 
PZ and TZ (Rho = -0.537). Bottom: MTR compared to Dapp in PZ and TZ tumours (Rho = -0.024).  
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Figure 3.10. Correlation plots between assessed MTR and Kapp. Top: MTR compared to Kapp in 
normal PZ and TZ (Rho = 0.570). Bottom: MTR compared to Kapp in PZ and TZ tumours (Rho = 0.141).  
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Additional incidental findings that could be appreciated on the MTR maps and source MT 
images were haemorrhage, calcification, and utricle cysts (Figure 3.11). 
 
 
Figure 3.11. Features demonstrated by Magnetization Transfer Imaging. Top row: haemorrhage 
shown as high signal on T1 weighted imaging (arrows) appears as high signal on MT on and off 
imaging and low signal on MTR. Middle row: calcification appears as low signal on T1, MT on, MT off 
and MTR maps (arrows). Bottom row: Utricle cyst in the midline at the base shown as high signal 
fluid structure on T2 weighted imaging (arrows) appears as high signal on MT on, isointense on MT 
off and low on MTR. 
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3.4 Discussion 
In this study we compared magnetization transfer imaging and non-Gaussian diffusion 
kurtosis imaging to conventional mpMRI sequences for the detection of prostate cancer in a 
re-biopsy population, using targeted transperineal biopsy as the reference standard. All 4 
measured parameters were able to distinguish benign from tumour tissue, but performed 
poorly at differentiating low (GS 3+3) from higher grade (GS ≥3+4) disease. Standard 
diffusion-weighted imaging ADC maps showed a moderate overall inverse correlation with 
both Kapp and MTR, but there was no observable correlation between MTR maps and DKI 
parameters within tumours. 
 
A number of previous studies have looked at the ability of DKI to differentiate tumour grade 
compared to benign tissue in comparison with standard diffusion-weighted imaging with 
monoexponential modelling. DKI parameters have repeatedly been shown to distinguish 
benign from tumour tissue, with several studies suggesting that the kurtosis metric K 
outperforms ADC for differentiating low and higher grade tumours [8, 9, 21-23]. 
Additionally, these studies also note a strong inverse correlation of K with ADC, as 
supported in our data (r = -0.641), raising the question of the additional clinical benefit over 
existing DWI sequences, given the increased technical complexity of DKI, particularly 
regarding the need for complicated post-processing and interpretation. Indeed, more recent 
work and a large retrospective study using prostatectomy as a reference standard suggested 
no additional benefit of DKI sequences [10, 24]. A possible explanation is the use of a 
clinically-derived ADC map (using a high b-value of 1000) in these studies, in contrast to 
earlier work where the ADC map was derived from the DKI sequences with high b-values 
ranging from 1400-2000 s/mm2. Current guidelines caution against using such high b-values 
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for ADC calculation due to the non-monoexponential decay at higher b-values, and due to 
concerns about reduced signal-to-noise ratio and noise-floor bias [4], which may have 
affected the performance of the ADC measurements in these studies. We also derived ADC 
maps from standard clinical DWI sequences, which may explain the lack of added benefit of 
DKI parameters. 
 
There have been two previous studies investigating the utility of MTI in prostate cancer [15, 
16]. Both were performed at 1.5T, assessed only PZ tumours, used systematic TRUS biopsy 
as a reference standard, and did not differentiation between Gleason grade. Of note the 
former study reported whole peripheral zone MTR values for tumour in the 12 patients with 
PCa. Our results support the findings of these studies that normal TZ and PZ tumour have a 
higher MTR than normal PZ. The difference in MTR between normal PZ and benign TZ is to 
be expected given the difference in composition of the tissue types, and the lower value 
may be explained by the PZ having a relatively loose stroma, a larger extracellular space, 
and a fluid-filled glandular cavity [25]. The mean MTR values derived here are comparable 
to the Arima et al study [16] for both normal TZ (26.9% vs 25.5%) and PZ tumour (25.0% vs 
30.6%), but higher than the Kumar et al study (7.01% and 8.29%, respectively) [15]. 
Conversely our results for normal PZ (20.0%) were much higher than these two studies 
(8.0% and 6.15%, respectively). This discrepancy may relate to the fact that MTR is an 
arbitrary measure and depends on the characteristics of the pulse sequence, the Kumar 
study differed to ours in being a 2D sequence, with a long TR. In addition, the earlier studies 
may have differences relate to residual haemorrhage post biopsy, which will predominantly 
affect the PZ rather than the TZ when systematic TRUS biopsy is performed, but will typically 
be excluded from areas containing cancer [26], thus only normal PZ rather than TZ or PZ 
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tumour will be affected. As expected, given the different values between normal PZ and TZ, 
zonal differentiation was readily distinguished in the majority of cases (Figures 3.1 and 3.2).  
 
A number of previous studies have shown ADC to decrease as tumour Gleason grade 
increases, however, there tends to be a degree of overlap of values between grades [27-29]. 
Although there was a trend for lower ADC values in higher grade (Gleason ≥3+4) tumours in 
our cohort this was non-significant which may relate to the relatively small sample size, 
particularly within the PZ. MTR showed moderate correlation to both Kapp (r=0.570) and Dapp 
(r=-0.537) in normal tissue, yet no correlation in tumour tissue (r=0.141 and -0.024, 
respectively).  Of note, there was a non-significant trend for increasing Kapp, but conversely 
lower MTR in higher grade transition zone tumours. These divergent results combined with 
the poor correlation of MTI and DKI, suggest that the techniques offer different but perhaps 
complementary information on the tumour microenvironment. Interestingly both tumour 
Kapp and MTR showed a higher inverse correlation to ADC (r=-0.444 and -0.459, 
respectively), suggesting that cellularity is contributing to these metrics, whilst other factors 
are contributing to their divergent values. At higher Gleason grades, the glandular structure 
of the prostate is progressively disrupted with increased cellularity and a reduction in the 
stromal matrix and luminal space [30]. This increased heterogeneity can therefore help to 
explain a trend for higher Kapp values observed in higher grade tumours [8]. Higher grade 
prostate cancer is expected to result in an increased amount of intracellular bound water 
molecules due to increased cellular density [31], but this will be counteracted by a 
breakdown of the normal extensive extracellular matrix [32]. These competing processes 
may balance, leading to no overall change in MTR. However, histological studies directly 
assessing cellularity, stroma and luminal spaces would be required in order to confirm these 
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theories. 
 
3.4.1 Limitations 
Our study has a number of limitations. Although benefiting from a prospective design, the 
analysis was performed in a retrospective nature and DKI and MTI values did not inform 
biopsy decision making. The numbers within the cohort were relatively low, this may have 
particularly affected attempts to differentiate low and higher grade tumours, where further 
sub-division became necessary. The added value of DKI and MT imaging was not directly 
assessed as this would require application of a multivariate model, which was not 
performed due to limited numbers. The statistical testing was performed without 
Bonferroni corrections and the correlations described should therefore only be considered 
as hypothesis generating. Targeted biopsy ensured that tissue was sampled from the 
outlined lesion, however, as with any biopsy technique this is prone to sampling error and 
may misclassify grade compared to the more robust gold standard of prostatectomy. 
Targets were prospectively chosen based on standard clinical mpMRI sequences, this may 
have led to a bias towards lesions with restricted diffusion and low ADC, particularly within 
the PZ where this is considered the key diagnostic sequence.  
 
We used a kurtosis model, however, other methods can be used to characterize the 
diffusion signal decay curve, including bi-exponential and stretched exponential models [5, 
6]. The bi-exponential model separates water diffusivity into two pools, one with fast and 
one with slow diffusion, whilst the stretched model views water diffusion as multiple 
Gaussian compartments with a wide diffusivity distribution [33-35]. However, given the 
increased noise apparent in clinical datasets, the DKI model was chosen as this is considered 
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more robust, and only contains two unknown parameters (Dapp and Kapp) that need to be 
estimated [5, 36, 37]. Another consideration would be the use of multidirectional diffusion 
tensor imaging, which assesses the anisotropic directionality of diffusion kurtosis but 
requires diffusion images in at least 15 different directions [38]. Given the prohibitive scan 
time, this approach has been considered unnecessary for oncologic imaging in the body, 
with DKI typically being performed based on a directionless "trace" of the diffusion tensor 
[5]. 
 
3.4.2 Conclusions  
In conclusion, ADC, MTI and DKI readily distinguished benign tissue from tumour, but none 
of the measured parameters reliably differentiated lower and higher-grade disease. 
Differences between DKI and MTI at higher Gleason grades may be explained by the balance 
between changes in cellularity, stromal matrix, and luminal space. DKI and MTI may 
therefore offer different but potentially complimentary information on the tumour 
microenvironment, with the former sensitive to alterations in tissue heterogeneity and the 
latter to changes in composition of the extracellular space. 
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Chapter 4: Quantification of total and intracellular tumour sodium concentration in 
prostate cancer patients 
 
4.1 Introduction 
Standard clinical MRI provides information about the distribution and environment of 
hydrogen nuclei, and is termed 1H-MRI. As hydrogen in tissues is most abundant in water, 
1H-MRI largely measures the distribution of water in tissues. However, MRI can also be used 
to detect several nuclei other than hydrogen which are MR-active, for example: 13C, 15N, 31P, 
19F. The images produced from these different nuclei (known generically as “X-nuclei” MRI) 
allow for other physical and metabolic processes to be studied in the human body.  
 
Sodium (23Na) MRI is a technique which aims to image this vital intra- and extracellular ion. 
23Na produces the second strongest MRI signal among all nuclei present in biological tissues 
given the abundance of sodium in vivo. However, the MRI sensitivity for sodium is around 
9.2% of protons and sodium concentration in vivo is around 2,000 times lower than the 
concentration of protons, resulting in signal-to-noise (SNR) ratios up to 20,000 times lower 
than 1H-MRI [1]. In addition, the short biexponential transverse relaxation time arising from 
the 3/2 spin of the quadrupolar nucleus produces further challenges in acquiring images 
with sufficient SNR, making 23Na-MRI a challenging technique [2]. This SNR deficit has been 
partly overcome by new techniques and higher-field strength magnets, allowing acquisition 
in a reasonable time frame (10 to 15 minutes) and with a resolution of a few millimetres, 
making 23Na-MRI a viable addition to existing 1H-MRI protocols [3]. Typically tissue sodium 
concentration (TSC) is measured, which represents a combination of the volume fraction 
weighted mean of the intracellular and extracellular sodium concentrations. 
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Sodium is an essential component of cellular metabolism and is actively exchanged via the 
Na/K and Na/H pumps to maintain intracellular pH.  Normal intracellular levels of sodium 
are 10 fold lower than extracellular concentrations. Changes in tissue sodium have been 
shown to occur in a wide range of disease processes including inflammation, ischaemia and 
in several tumour types [4-6]. Typically tissue sodium concentration (TSC) is measured, 
which represents a combination of the volume fraction weighted mean of the intracellular 
sodium concentration and the extracellular sodium concentration. There are a number of 
reasons why tumours will demonstrate a high TSC, but mainly because many cellular 
processes and interactions in excitable tissues depend on the maintenance of a low 
intracellular and high extracellular sodium concentration [7]. This gradient is maintained by 
the transmembrane sodium-potassium pump, powered by adenosine triphosphate (ATP), as 
well as other transporters. If the supply of ATP is insufficient due to impaired cellular energy 
metabolism, or if the cell membrane integrity is disrupted, then the intracellular sodium 
concentration will rise [8, 9]. Furthermore, proliferating cells have high intracellular sodium 
content secondary to increased activity of the Na+/H+ exchanger in the presence of reduced 
pH secondary to hypoxia and increased lactate [10, 11]. In addition, extracellular sodium will 
increase due to tumour neovascularization and an increase in the tumour interstitial space 
[12]. Thus, increases in both intracellular sodium concentration and extracellular volume 
can contribute to an increase in TSC and the measurement is sensitive to changes in both 
the metabolic state of tissues and integrity of cell membranes. 
 
Studying the sodium levels in prostate cancer could provide complementary information to 
traditional 1H-MRI. Previous 23Na-MRI studies on the prostate in man are limited, with only 3 
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published studies incorporating healthy volunteers and a further study investigating 3 
patients with biopsy-proven prostate cancer which did not quantify the tumour sodium 
concentration [13-16]. The aim of this work was to measure the tissue concentration of 
sodium within tumours and background normal prostate in patients with prostate cancer, 
using pathology from prostatectomy as the gold standard. 
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4.2 Methods 
 
4.2.1 Patient Population 
The local institutional review board and ethics committee granted approval for this 
prospective study (CUH/16/EE/0205), with all participants signing written informed consent. 
15 patients with biopsy-proven intermediate or high risk prostate cancer underwent a 
dedicated research MRI prior to treatment with radical prostatectomy. Exclusion criteria 
included previous treatment for prostate cancer, or a clinical contraindication to MRI. 
 
4.2.2 Imaging of Phantoms  
In order to quantify tissue sodium concentration (TSC), it is necessary to image calibration 
markers containing known sodium concentrations. Imaging was performed using a 
dedicated dual-tuned 1H/23Na receiver endorectal coil (ERC; GE Healthcare, Waukesha, WI) 
[17]. Initial phantom work was undertaken to determine the ERC reception profiles in order 
to inform interpretation of sodium maps in vivo, with a phantom replacement method used 
to create a calibration curve. The ERC was placed in the centre of an arrangement of 5 x 50 
ml Falcon tubes, with the content of NaCl in 4 % agar phantoms varying between 7 and 160 
mM/L NaCl. This was used to create a calibration curve which was applied to the in vivo data 
to create sodium maps [18]. Images were acquired using both ERC as “receive” coil for 23Na 
and also a standard “body coil” as receive-coil for “1H” (standard clinically-used proton 
imaging); Figure 4.1.   
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4.1 Phantom Imaging. A phantom replacement method was used to create a calibration curve 
against 5 NaCl in 4 % agar phantom tubes varying between 7 and 160 mM/l NaCl (indicated by 
circular outlines), with the sodium-endorectal coil placed centrally (red outline). 
 
4.2.3 Magnetic Resonance Imaging  
All phantom experiments and clinical imaging was performed on a clinical 3T system (GE 
MR750, GE Healthcare, Waukesha, WI) using a dedicated 13C clamshell exciter (GE 
Healthcare, Waukesha, WI) and a dual-tuned 1H/23Na receiver ERC.  
 
Sodium imaging was performed using a 3D cones [19, 20] sequence with the following 
imaging parameters: TE = 0.5 ms, TR = 60 ms, FOV = 30 cm, nominal resolution 2.35 x 2.35 x 
4 mm, 12 NEX, 6468 total readouts, 7 minutes acquisition duration. For region of interest 
(ROI) outlining, 1H FRFSE T2-weighted anatomical images were acquired using the following 
parameters: TE = 105 ms, TR = 2500 ms, FOV = 30 cm, resolution 0.5 x 0.5 x 4 mm. 
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4.2.3.1 Intracellular sodium measurements 
For intracellular-weighted imaging, the sodium sequence was repeated with the addition of 
a 5.6 ms adiabatic inversion pulse with inversion time (TI) = 30 ms, TR = 120 - 210 ms, 
resolution and FOV as before, 10 NEX, 5390 total readouts, 11 – 19 minutes acquisition 
duration. For the inversion recovery sodium imaging, TR and therefore total acquisition 
duration was varied due to specific absorption ratio (SAR) limitations. Sodium images were 
corrected for receive sensitivity by dividing the images by a heavily smoothed duplicate of 
themselves (Gaussian kernel, sigma = 5) [21]; Figure 4.2. 
 
Figure 4.2. Sensitivity-corrected images. Proton T2-weighted image (top row) and TSC images 
(bottom row) of the prostate, with endorectal coil in situ (*). The uncorrected images (left) were 
adjusted for receive sensitivity by dividing the images by a heavily smoothed duplicate of themselves 
to create the corrected images (right). Images displayed at full dynamic range. Colour scale is an 
arbitrary measure of signal intensity due to sensitivity correction being performed prior to the maps 
being generated. 
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The Inversion Recovery (IR) technique for assessing intracellular sodium is based on sodium 
nuclei having a significantly longer T1 relaxation time in the extracellular fluid space as 
compared to intracellular sodium, meaning IR can be used to weight the contribution of 
sodium signal from either environment [22 - 24]. 
 
4.2.4 Histopathology assessment 
Prostatectomy specimens were fixed in formalin and oriented by the location of the seminal 
vesicles, posterior surface of the prostate, and by the position of the urethra. The apical 
cone was amputated, and sliced into 4 mm sections from left to right, the remaining gland 
was cut transversely into 5 mm whole-mount parallel slices in the horizontal plane from 
inferior to superior. Representative 5 μm microtome slides were processed from each 5 mm 
whole-mount slices for histopathological analysis. Tumour was outlined on hematoxylin and 
eosin (H&E) stained sections from each slice by an experienced uropathologist specializing in 
prostate cancer. 
 
4.2.5 Correlation of histopathology to imaging 
A radiologist with 7-years’ experience reporting clinical prostate MRI used the 
histopathological tumour maps in conjunction with the available diagnostic MRI datasets to 
outline the peripheral zone (PZ), transition zone (TZ) and tumour. The tumour location from 
histopathological slides was manually copied as a region-of-interest (ROI) onto the T2-
weighted anatomical image acquired using the ERC. ROIs of a minimum volume of 0.5 cm3 
were additionally drawn on at least 3 consecutive slices for normal TZ and PZ, with care 
taken to avoid partial volume effects from the urethra, bladder, seminal vesicles, and extra-
prostatic tissue, and at the zonal interface. Separately, in order to assess whether the 
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reduced SNR in the anterior gland affected estimates of sodium concentration, ROIs in all 
patients were drawn in the anterior half and posterior half of the TZ. ROIs based on these 
outlines were then copied to the co-localised sodium images using OsiriX 8.5.1 (Pixmeo 
SARL, Bernex, Switzerland). 
 
4.2.6 Statistics 
A balanced one-way ANOVA was performed to compare the results from each patient for 
normal PZ, normal TZ and tumour ROIs, using Tukey’s test for multiple comparisons. A two-
sided Wilcoxon rank sum test was used to assess for differences in sodium values between 
tumour grades.  A p-value of < 0.05 was considered statistically significant. 
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4.3 Results 
All scans were acquired without complications. 15 patients were included in the study 
group, with a median age of 59.5 years (mean 60.7, range 48 - 73 years) and a median pre-
biopsy PSA level of 8.4 ng/mL (mean 9.79, interquartile range 6.125 - 11.6 ng/mL); Table 4.1. 
The average time between diagnostic prostate biopsy and MRI was 89.6 days (range 43 – 
179 days). 8 patients underwent MRI scanning on the day of surgery, the mean time from 
MRI to surgery was 5 days (range 0 - 31 days). 
 
Characteristic Value 
Patient age, years 59.5 (56.25 – 64.5) 
PSA level, ng/mL 8.4 (6.125 – 11.6)   
Pathological tumour volume, cm3 3.25 (1.54 – 6.76)   
Final lesion Gleason score (n = 17)  
3+3 1 
3+4 7 
4+3 5 
3+5  2 
4+4  0 
≥9 2 
Pathologic tumour stage (n = 15)  
T2a 0 
T2b 1 
T2c 3 
T3a 10 
T3b 1 
 
Table 4.1. Patient Characteristics. Median values listed, Inter-quartile range in parenthesis  
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17 tumours were detected in the 15 patients imaged, with pathology Gleason score 3+3 (n = 
1), 3+4 (n = 7), 3+5 (n = 2), 4+3 (n = 5), and 4+5 (n = 2). The mean tumour size at final 
pathology was 4.37 cm3 (range 0.09 – 15.78 cm3). Two patients had significant artefact on 
the sodium imaging and had to be excluded (Gleason 3+4 and 4+5 tumours), and in one 
further patient, intracellular weighted sodium data could not be acquired due to a software 
fault (Gleason 3+4 tumour).  
 
The average tissue sodium concentration (TSC) was significantly higher in the normal 
peripheral zone at 39.2 mmol/L (range 34.2 – 42.5) compared to the normal transition zone 
32.9 mmol/L (range 28.4 – 39.5); p <0.001, Figure 4.3. The mean TSC for all tumours was 
43.1 mmol/L and for PZ tumours was 45.0 mmol/L (range 38.5 – 50.9); Table 4.2, Figure 4.4. 
Overall 11/13 peripheral zone tumours demonstrated a higher TSC than the corresponding 
normal PZ on the contralateral side of the gland and there was a significant difference 
between PZ tumour compared to both the normal PZ (p <0.001) and normal TZ (p <0.001); 
Figure 4.5. 2 of 15 tumours were location in the TZ and demonstrated a mean TSC of 30.6 
and 33.2 mmol/L, respectively with both TZ lesions having a slightly lower TSC than the 
corresponding normal TZ. 
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Figure 4.3. Sodium concentration in the normal PZ and TZ. 58 year old man, PSA 18.69 ng/mL with a 
pathologically proven Gleason 3+5 tumour in the left apex TZ (not shown). Regions of interest 
outline normal peripheral zone (blue) and normal transition zone (yellow) of the prostate; 
endorectal coil in situ. Left: T2-weighted axial image. Middle: Map of tissue sodium concentration 
(TSC). Right: Map of intracellular sodium concentration. The mean TSC and intracellular sodium 
concentrations were 40.6 and 10.2 mmol/L in the PZ, and 32.7 and 7.9 mmol/L in the TZ, 
respectively. 
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Patient Normal TZ Normal PZ Tumour 
location 
Tumour Tumour 
volume 
Gleason 
Grade 
1 32.7 (± 0.8) 40.6 (± 2.6) TZ 30.6 (± 1.0) 7.51 3+5 
3 34.2 (± 0.8) 39.4(± 2.6) PZ 49.4 (± 4.6) 2.29 3+4 
4 (lesion 1) 33.4 (± 1.1) 41.7(±.3.0) TZ 30.8 (± 1.8) 6.50 3+4 
4 (lesion 2) - - PZ 47.5 (± 5.7) 0.29 3+4 
5 28.4 (± 1.4) 40.1 (± 2.2) PZ 46.2 (± 1.4) 3.56 3+4 
6 39.5 (± 1.1) 37.4 (± 1.5) PZ 47.5 (± 1.4) 3.18 4+3 
8 33.0 (± 2.0) 41.2 (± 2.2) PZ 50.9 (±0.4) 3.25 4+3 
9 29.1 (± 1.7) 36.2 (± 4.0) PZ 38.5 (± 1.6) 0.79 3+4 
10 32.7 (± 2.3) 39.4 (± 1.9) PZ 44.6 (± 2.9) 0.70 4+3 
11 33.5 (± 1.3) 37.9 (± 2.9) PZ 41.1 (± 2.4) 15.78 3+4 
12 31.5 (± 1.6) 37.9 (± 0.9) PZ 41.8 (± 0.8) 2.29 4+3 
13 (lesion 1) 32.1(± 1.4) 34.2 (± 2.0) PZ 43.6 (± 3.8) 3.85 3+3 
13 (lesion 2) - - PZ 48.0 (± 2.7) 0.09 3+5 
14 35.8(± 0.38) 42.4 (± 3.3) PZ 46.9 (± 0.4) 1.12 4+5 
15 32.2(± 2.4) 40.8 (± 1.7) PZ 39.6 (± 2.2) 4.99 4+3 
Group mean 32.9 39.2 - 43.1 3.75 - 
 
Table 4.2. Tissue Sodium Concentration (in mml/L) for normal and tumour tissue; standard 
deviation in parenthesis. Patients 2 and 7 excluded due to artefact. TZ = transition zone, PZ = 
peripheral zone. 
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Figure 4.4. Sodium concentration in PZ tumour. 63 year old man, PSA 8.4 ng/mL with a 20 mm 
pathologically proven Gleason 4+3 tumour in the right mid PZ, with focal extracapsular extension 
(arrow in diagnostic T2-weighted image of the prostate, left); endorectal coil in situ. Middle: TSC 
map; right: TSC map overlaid on T2 image. The mean TSC and intracellular sodium concentrations in 
the lesion were 41.8 and 19.2 mmol/L, compared to 37.9 and 17.1 mmol/L in the normal PZ, 
respectively. 
 
 
 
Figure 4.5. Box and whiskers plot of the tissue sodium concentration in normal and PZ tumour 
tissue. Top and bottom of boxes represent 25th and 75th percentiles of, lines in boxes represent the 
median value and bars represent the data within 1.5 times interquartile range, + denotes outliers. P-
values between groups as indicated. PZ: normal peripheral zone; TZ: normal transition zone.  
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The mean intracellular-weighted sodium was also significantly higher in the normal PZ (17.5 
mmol/L, range 10.2 – 21.4) compared to the normal TZ (14.7 mmol/L, range 7.9 – 18.0; p = 
0.02). The average intracellular-weighted sodium for all tumours was 18.7 mmol/L and for 
PZ tumours was 19.9 mmol/L (range 15.8 – 22.3). Overall 9/12 PZ tumours demonstrated a 
higher intracellular sodium compared to the normal PZ on an individual patient level but this 
did not reach significance (p = 0.05); however, there was a significant difference between 
the PZ tumour tissue and the normal TZ (p < 0.001); Figure 4.6. Both TZ lesions had slightly 
higher intracellular sodium values than the normal TZ; Table 4.3. 
 
 
Figure 4.6. Box and whiskers plot of intracellular weighted sodium concentration in normal and PZ 
tumour tissue. Top and bottom of boxes represent 25th and 75th percentiles of data, lines in boxes 
represent the median value and bars represent the data within 1.5 times the interquartile range, + 
denotes outliers. P-values between groups as indicated. PZ: normal peripheral zone; TZ: normal 
transition zone. 
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Patient Normal TZ Normal PZ Tumour 
location 
Tumour Tumour 
volume 
Gleason 
Grade 
1 7.9 (± 2.5) 10.2 (± 3.2) TZ 8.6 (± 3.1) 7.51 3+5 
3 16.1 (± 0.3) 18.1 (± 1.1) PZ 21.5 (± 1.1) 2.29 3+4 
4 (lesion 1) 14.6 (± 0.7) 18.4 (± 1.0) TZ 14.7 (± 2.8) 6.50 3+4 
4 (lesion 2) - - PZ 20.8 (± 2.7) 0.29 3+4 
6 16.0 (± 1.3) 18.2 (± 2.0) PZ 20.6 (± 1.2) 3.18 4+3 
8 14.7 (± 0.9) 16.4 (± 1.4) PZ 21.9 (± 0.2) 3.25 4+3 
9 14.0 (± 1.0) 15.2 (± 2.3) PZ 15.8 (± 3.3) 0.79 3+4 
10 15.6 (± 1.3) 19.0 (± 1.2) PZ 19.2 (± 0.8) 0.70 4+3 
11 15.1 (± 1.1) 21.4 (± 1.4) PZ 17.7 (± 0.5) 15.78 3+4 
12 14.3 (± 0.8) 17.1 (± 0.6) PZ 19.2 (± 0.2) 2.29 4+3 
13 (lesion 1) 15.0 (± 0.7) 17.6 (± 1.0) PZ 21.7 (± 2.1) 3.85 3+3 
13 (lesion 2) - - PZ 21.2 (± 2.7) 0.09 3+5 
14 18.0 (± 0.3) 17.6 (± 1.0) PZ 22.3 (± 0.5) 1.12 4+5 
15 15.3 (± 1.4) 17.6 (± 1.0) PZ 17.3 (± 0.4) 4.99 4+3 
Group mean 14.7 17.5 - 18.7 3.76 - 
 
Table 4.3. Intracellular weighted Sodium Concentration (in mmol/L) for normal and tumour tissue; 
standard deviation in parenthesis. Patients 2 and 7 were excluded due to artefact; the intracellular 
weighted imaging was excluded for patient 5 due to software acquisition error. TZ: transition zone, 
PZ: peripheral zone. 
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Regional assessment of the differences in signal between the anterior and posterior gland 
showed a significant variation. The mean TSC value in the anterior TZ was 30.51 mmol/L (± 
1.67) compared to 33.48 mmol/L (± 1.86) in the posterior TZ; p = 0.004. The mean 
intracellular sodium value was 14.32 mmol/L (± 0.82) in the anterior TZ, compared to 15.53 
mmol/L (± 1.06) in the posterior TZ; p = 0.08.  
 
A comparison between tumour grade and sodium concentration was also performed. For 
peripheral zone lesions, 7 patients had 3+3 or 3+4 tumours, and 6 patients had tumours 
with grade ≥Gleason 4+3. The mean TSC was lower in those with Gleason ≤3+4 (44.4 
mmol/L) compared to those with ≥4+3 (45.6 mmol/L), but this was not statistically 
significant; p = 0.19. Likewise, there was no significant difference in mean intracellular 
sodium between low grade and higher grade tumours: 19.5 mmol/L (Gleason ≤3+4) and 
20.2 mmol/L (≥4+3); p = 0.29.  
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4.4 Discussion 
This study demonstrated the ability to quantify tissue sodium concentration (TSC) and 
intracellular sodium concentration in both tumours and normal prostate tissue. TSC has 
previously been quantified in the normal PZ and TZ of both volunteers and patients. Here 
we demonstrate sodium imaging at a higher spatial resolution than previously achieved and 
quantify both TSC and intracellular sodium concentrations within prostate tumours for the 
first time. We have shown a significant increase in total tissue sodium concentration in 
tumours compared to normal tissue, and a higher intracellular sodium in tumours compared 
to normal TZ.  
 
We found a significant difference between intracellular sodium in normal PZ and TZ (17.5 
and 14.7 mmol/L, respectively). The values measured are within the expected range for 
other tissues, with intracellular sodium concentration reported to be around 10 - 15 mmol/L 
[1, 25, 26]. It is possible that the higher values demonstrated in the normal PZ may reflect 
differences in cellularity and sodium gradients across the membrane between the tissues, 
with more metabolically active PZ cells requiring more nutrients [14]. Previous studies 
support our findings of a higher tissue sodium concentration in normal PZ compared to TZ 
[13, 14, 16]. These studies show a wide range in normal PZ TSC concentration from 40.4 - 
70.5 mmol/L and TZ from 28.3 - 60.2 mmol/L, which may relate to technical differences, 
spatial resolution and/or the effects of partial voluming. We found the mean concentrations 
in the PZ and TZ of our study population to be at the lower end of this range (39.2 and 32.9 
mmol/L, respectively). Physiologically, extracellular sodium concentration (140 - 150 
mmol/L) is an order of magnitude higher than intracellular sodium concentration; however, 
the extracellular volume fraction (including vessels) accounts for only around 20% of total 
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tissue volume [1, 26]. The higher percentage contribution of intracellular sodium would 
therefore give an expected TSC in the range of 36 - 42 mmol/L within normal tissues and is 
therefore supportive of our measurements. It is not unexpected that TSC levels differ 
between normal PZ and TZ, given the differing composition of their respective tissues, with 
the normal PZ having a glandular structure with an extensive duct system, a relatively loose 
stroma, and a larger extracellular space [27 - 29]. Furthermore, Hausmann et al [13] showed 
that TSC measurements of the normal PZ and TZ correlated to their respective ADC 
measurements. Although the young age of the volunteers imaged (26 - 34 years) may limit 
the applicability of the findings in the TZ of this population to patients who are usually older, 
the results support a relationship between the increased extracellular space of the glandular 
PZ (and free diffusion of water) and higher concentrations of sodium in normal prostatic 
tissue. Of note, we found a small, but significant difference in TSC but not intracellular 
sodium between the posterior and anterior TZ, which may relate to reducing SNR with 
increasing distance from the coil. 
 
We demonstrated significantly higher TSC in PZ tumours compared to both normal PZ and 
normal TZ. Such a result demonstrates that the change in sodium concentration in tumours 
is measuring more than a simple change in cellularity: tumours have a higher cell density 
compared to the normal PZ, as demonstrated by ADC, but given that intracellular sodium is 
significantly lower than extracellular sodium, cellular changes alone would lead to a 
reduction and not an increase in TSC. Intracellular sodium in peripheral zone tumours was 
higher than normal PZ and TZ, but only reached significance when compared to the TZ; this 
could be a reflection of changes in cellularity alone. Taken together, these results are 
suggesting that there is an increase in extracellular sodium concentration in PZ tumours. 
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Interestingly, the two TZ tumours imaged demonstrated lower sodium concentrations, this 
may be partly explained by the drop-off in SNR with increasing distance to the coil, with PZ 
tumours unlikely to be affected due to their relative proximity to the coil. However, the 
lower values relative to normal TZ suggest this is a genuine finding and indicative of a 
different sodium environment in TZ versus PZ tumours. Indeed, TZ tumours have been 
described as having morphological differences to PZ tumours, having well-differentiated 
glands of variable size and being lined by columnar cells with a clear cell histological pattern 
[30, 31]. However, the number of TZ lesions in the cohort is small and further investigation 
is warranted. 
 
In healthy tissues, the large sodium concentration gradient between intra and extracellular 
sodium is maintained by several transporters and pumps, the most important being Na+/K+-
ATPase [32]. Therefore, a potential advantage of sodium imaging over proton MRI is the 
ability to provide functional information relating to tissue viability, cell membrane integrity, 
and energetic status of the cellular environment. In tumours, changes in TSC may reflect 
both increases in intra- and extracellular sodium as well as changes in the size of each 
compartment. Increases in cell density will reduce the extravascular extracellular space and 
TSC will be weighted towards the low concentration sodium from the intracellular 
compartment. Conversely, an increased interstitial space will increase the extracellular 
weighting of the TSC measurement. Intracellular sodium in tumour cells may rise when 
demand for ATP exceeds production, limiting the ability of the Na+/K+-pump to maintain the 
sodium gradient or due to over-activity of the Na+/K+-pump to compensate for the low pH of 
the tumour microenvironment induced by hypoxia and increased lactate [1, 10, 11]. TSC has 
been shown to be elevated in several tumour types and has the potential to demonstrate 
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treatment response in a number of conditions such as breast cancer [33], murine models of 
prostate cancer [34], and successful ablation of uterine fibroids [35]. There may be several 
potential applications for sodium-MRI in prostate cancer, including primary tumour 
localization and characterization in select cohorts, monitoring treatment response to 
oncological agents and detecting local recurrence following radical therapy. Furthermore, 
any treatment that causes cell death or loss of membrane integrity such as ablative focal 
therapy techniques, several of which are being trialed in prostate cancer, could be 
monitored with sodium MRI. 
 
4.4.1 Limitations  
Our study has some limitations. The patient numbers were relatively small for this 
exploratory study, and TZ tumours were under-represented in the cohort. The selection bias 
of patients undergoing prostatectomy limits the ability to differentiate grade type in this 
cohort, with an over-representation of Gleason 3+4 and 4+3 disease. Patients were selected 
on the basis of lesions detectable on standard clinical prostate mpMRI and therefore the 
added value of the technique for detecting lesions de novo was not assessed. We did not 
correlate TSC with ADC measurements derived from diffusion-weighted imaging. Although 
previous work demonstrated a correlation between TSC and ADC in normal prostatic tissue, 
our results suggest that these values are likely to be divergent in tumour tissue, but 
warrants further investigation. The detection of sodium signal in vivo remains challenging 
and improvements in hardware and software and/or increasing magnet strength are needed 
to help improve SNR and resolution and reduce acquisition times and make this promising 
technique more clinically available. 
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4.4.2 Conclusions  
In conclusion, we have successfully quantified the tissue and intracellular concentrations of 
prostate tumours in vivo, demonstrating a significant increase in TSC within PZ tumours, and 
highlighting the potential of this non-invasive functional imaging technique in the 
investigation of patients with prostate cancer. 
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Chapter 5: The value of 11C-acetate PET-CT in identifying prostate cancer and 
differentiating tumour from benign prostatic hypertrophy  
 
5.1 Introduction 
Positron emission tomography (PET) using the tracer 18F-FDG has become part of routine 
clinical practice for staging and the assessment of treatment response in a number of 
cancers. However, the use of 18 F-FDG is limited in prostate cancer due to the reduced 
glycolytic activity of low to intermediate Gleason grade tumours and artefact related to 
tracer activity in the adjacent bladder [1]. 11C-acetate PET-CT has shown promise in 
detection of prostate cancer, nodal disease and bone metastases [2, 3]. The rationale is the 
preferential utilisation of fatty acid metabolism for energy production in prostate cancer, 
with acetate being a naturally occurring fatty acid pre-cursor which is rapidly metabolized 
into acetyl-CoA, and employed to build membrane fatty acids [4]. An added advantage is the 
respiratory route of excretion of the tracer (via breakdown into 11CO2), with minimal bladder 
activity. However, exhalation of the agent brings additional challenges, with possible 
radiation exposure to staff, the potential to release a radioactive gas into the atmosphere 
and increased background noise leading to degradation of the images acquired.  
 
Recent work by Jambor et al [5, 6] and Mena et al [7] has shown promise for the use of 11C-
acetate for local detection of prostate cancer. However, despite increased uptake in 
prostate tumours compared to normal prostate, there was significant overlap with benign 
prostatic hypertrophy (BPH), resulting in no overall benefit compared to mp-MRI. The half-
life of 11C is 20.38 minutes, and as such, imaging is typically performed 10-20 minutes after 
tracer injection [8]. However, later time-point imaging is feasible and has been shown to 
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help distinguish hepatocellular carcinoma from focal nodular hyperplasia in the liver [9], and 
may be beneficial in allowing clearance of the tracer from the background blood pool. 
 
Acetate is a fatty acid precursor that is converted to acetyl-CoA and oxidised in the 
tricarboxylic acid (TCA) cycle. Injected 11C-acetate is rapidly converted into TCA cycle 
intermediates and CO2, but can also be used for fatty acid synthesis resulting in 
accumulation of 11C into lipids [10, 11]; thus later imaging may preferentially show acetate 
uptake in cancer with an increased tumour-to-background ratio. Recent work in prostate 
cancer using murine C42b xenografts is supportive of this, with optimal contrast occurring at 
the 60-90 minute time-point [12]. Patlak analysis of dynamic data suggests that during the 
early time period, the reversibly labelled tumour pool, representing tricyclic acid cycle 
metabolites and bicarbonate was dominant, whereas after 17.5min, the irreversibly labelled 
pool representing tumour lipid dominance. This would be supported by clinical data which 
suggests that 50% - 80% of injected acetate is metabolized to bicarbonate by the 10-15 
minute time point [3, 13]. Uptake of acetate by tumour cells may also depend on the 
tumour microenvironment, with tumour cells having an increased excretion of acetate 
under hypoxic conditions [14], and uptake of acetate tracers shown to increase when 
oxygen levels are reduced [15, 16].  
 
It was therefore hypothesised that late (up to 90 minutes) 11C-acetate PET-CT imaging in 
patients is feasible, and it may be that at later time-points prostate cancer foci will 
demonstrate tracer uptake in tumour lipids to enable improved tumour-to-background 
detection and further differentiation of tumour from BPH may be aided due to the blood-
pool clearance of tracer from hypervascular BPH nodules.  
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5.2 Methods 
 
5.2.1 Patient population 
9 patients with biopsy-proven intermediate or high risk prostate cancer were prospectively 
enrolled and underwent a dedicated research PET/CT prior to treatment with radical 
prostatectomy. Participants were recruited between September 2016 and May 2017, with 
written informed consent obtained in all cases. Approval for the study was granted by the 
institutional review board, the local ethics committee (CUH/15/EE/0213), and the 
Administration of Radioactive Substances Advisory Committee (ARSAC, certificate reference 
RPC/83/400/33606). 
 
5.2.2 Soda lime trap 
In order to minimise the radiation expired into the room, a system was devised for trapping 
exhaled CO2 gas. A face mask was fitted and a closed tubing system employed with no 
valves and a continuous flow pump drawing exhaled air through a soda lime trap at ~ 20 
L/min (Figure 5.1).  
 
 
 
 
Figure 5.1 Schematic representation of the soda lime trap design. 
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A double medical grade disposable CO2 absorber was employed (Spherasorb™; Intersurgical, 
Wokingham, UK), with each containing 500 g of soda lime, with a capacity of 120 L/kg. 
Average exhaled volume is predicted to be 6 L per minute, based on a respiratory rate of 12 
breaths/minute and a tidal volume of approximately 0.5 L. Exhaled air contains 
approximately 4% CO2, therefore during a 90 minute study, 21.6 L CO2 will be expired; this 
requires 180g of soda lime absorbent (21.6L ÷ 120 L/kg capacity); Figure 5.2. There will also 
be a small contribution from CO2 within room air (0.04%), based on the pump speed of 20 
L/min over a 90 minute scan this will produce 0.72 L of CO2 (0.04% of 1800 L) and require an 
extra 6 g of soda lime absorbent (total = 186 g). 
 
 
 
  
Figure 5.2 Soda lime trap pre (left) and post (right) scanning. 
The beads demonstrate a colour change from white to violet with CO2 absorption. Each canister 
contains 250g; the degree of colour change is expected given the predicted 186g required. 
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5.2.3 PET/CT Imaging 
Subjects were scanned supine, with an oral-nasal face mask to collect respirated CO2. 
PET/CT scans were performed on a GE Discovery 690 (GE Healthcare, Waukesha, WI, US) at 
Addenbrooke’s Hospital, Cambridge, UK.  Immediately following a low-dose CT of the 
abdomen and pelvis for attenuation correction and anatomical localisation, patients 
received an intravenous bolus injection of up to 1500 MBq 11C-acetate [7]. Emission data 
were acquired in list-mode over 90 minutes in one bed position with the prostate centred 
axially in the FOV. List-mode data were binned in 54-time frames of increasing duration 
(12×5 s, 3×10 s, 6×15 s, 4×30 s, 5×60 s, 5×120 s, 10×150 s, 9×300 s) and reconstructed into a 
192x192x47 matrix with 3.12×3.12×3.27 mm voxels, using time-of-flight ordered-subsets 
expectation maximisation (TOF-OSEM) with 4 iterations and 24 subsets. Corrections for 
attenuation, scatter, randoms, dead time, normalisation, sensitivity and isotope decay were 
applied, together with an isotropic 4-mm full-width at half maximum Gaussian filter post 
reconstruction. The attenuation correction CT acquisition parameters were: tube voltage 
140kV, tube current 80mA, rotation time 0.5 seconds, pitch 1.375, slice thickness 3.75 mm 
reconstructed to 3.27 mm. Participants were not required to fast prior to their PET/CT 
examination.  11C-acetate was provided by the Wolfson Brain Imaging Centre, Cambridge, 
UK.  
 
The effective dose (ED) for 11C-acetate has been estimated to be 0.0049 mSv/MBq [17], 
hence, for an administered activity of 1,500 MBq, the ED is 7.4 mSv. The ED for the low dose 
CT component of the examination was estimated at 0.7 mSv, giving a total estimated ED of 
8.1 mSv for the protocol. 
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5.2.4 Magnetic Resonance Imaging 
All participants underwent prostate MRI examinations as part of their clinical management, 
performed at 1.5-T or 3.0-T scanners using a surface coil and no endorectal coil. All studies 
met minimum PI-RADS version 1 sequence requirements [18] and included axial T1-
weighted images of the pelvis, high resolution axial T2-weighted images of the prostate and 
DWI with a minimum of two b values, with a high b value of ≥800 - 1,000. To avoid bias in 
selection of ROIs with high uptake on PET, the T2-axial MR images were utilised for the 
definition of ROIs for use in the analysis of the PET data as described in the following 
section. 
 
5.2.5 Image analysis 
PET, CT and MR image registration: Image registration was performed blinded to the clinical 
data of the participants and utilised models implemented within the Advanced 
Normalization Tools registration software (ANTs; Penn Image Computing and Science Lab, 
University of Pennsylvania, USA). The attenuation correction CT component of the 11C-
acetate examination of each patient was used as the reference space for all registrations 
performed in this study. 
 
To reduce the impact of patient motion during the 11C-acetate PET acquisition, the 54 
frames of the dynamic PET image series were non-rigidly registered to the time frame image 
corresponding to 55-60 min post tracer administration (frame 48).  Registration was 
performed using a 4-level multi-scale approach with affine initialisation and utilising 
normalised cross-correlation as the similarity metric.  Adjustment for local non-rigid 
deformations was performed using symmetric normalisation (SyN) with Gaussian 
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regularisation (3 voxels) of the update velocity fields and zero total field regularisation. The 
registered PET frames were averaged for the generation of a mean image, which was 
subsequently co-registered with the attenuation correction CT using affine transformation 
and a mutual information-based similarity.  
 
Registration of T2 MR images and PET data was performed using the attenuation correction 
CT as the intermediate link for spatially registering the datasets. To avoid the registration 
process being influenced by pelvic bone anatomy and structures distant to the prostate, 
sub-volume encompassing the prostate gland alone were utilised.  The quality of the results 
obtained by the registration process was visually inspected. The resulting transformation 
was subsequently applied to all 54 frames in the PET dynamic series. A schematic diagram of 
the registration process is presented in Figure 5.3 and 5.4.  
 
 
 
Figure 5.3: Schematic diagram of the image registration paradigm employed.   
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Figure 5.4. Fusion of PET/CT to MRI. PET/CT (top left) and T2-weighted axial MR images (top right) 
are fused via registration software using bony landmarks (bottom left), to create a fused PET/MRI 
image (bottom right) for assessment of pre-defined tumour and normal tissue ROIs from the 
diagnostic MRI sequences. 
 
 
Lesion-based analysis: Registered frames of the dynamic PET image series corresponding to 
6-10 min, 14-20 min, 20-30 min and 60-90 min post injection (p.i) were averaged, and 
utilised for the generation of standardised uptake value (SUV) images normalised by body 
weight. Tumour ROIs were delineated on the clinical diagnostic MRI by a radiologist with 7-
years’ experience reporting clinical prostate MRI; tumour ROI delineation included lesions in 
the peripheral (tPZ) and transition zones (tTZ). ROIs for normal prostate tissue in the 
peripheral zone (nPZ) and benign hyperplasia (BPH) were also delineated. ROI maps were 
transformed into the space of the attenuation correction CT and overlaid on the co-
registered PET SUV maps for the calculation of SUVmean, SUVmax and SUV60% (voxel values 
above a 60% iso-contour of SUVmax) in these areas. Target-to-background ratios (TBR) for 
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both tumour and BPH regions were determined by normalising SUVmax in these regions by 
SUVmean in normal PZ (tumour/nPZ and BPH/nPZ, respectively). Tissue time activity curves 
over the 90-min PET acquisition were derived by applying the ROIs onto the registered PET 
dynamic series.  
 
5.2.6 Histopathological correlation 
Prostatectomy specimens were fixed in formalin and oriented by the location of the seminal 
vesicles, posterior surface of the prostate, and by the position of the urethra. The apical 
cone was amputated, and sliced into 4 mm sections from left to right, the remaining gland 
was cut transversely into 5 mm whole-mount parallel slices in the horizontal plane from 
inferior to superior. Tumour was outlined on hematoxylin and eosin (H&E) stained sections 
from each slice by an experienced uropathologist specializing in prostate cancer. Each 
histopathology slice was manually co-registered to the corresponding PET/CT slice, with 
utilization of the diagnostic MR images where necessary.  
 
5.2.7 Statistical analysis  
Statistical analysis was conducted in Matlab 2016b (The Mathworks, Nattick, MA). Data are 
presented as n (%), mean (± standard deviation) or median [first quartile (Q1)-third quartile 
(Q3)] as appropriate. Linear mixed effects analysis was performed to assess the relationship 
between static PET parameters (SUV or TBR) and region type (nPZ, BPH or tumour). Region 
type and age were entered the model as fixed effects, while random effects included 
intercepts for subjects and regions, as well as by-region random slopes for the effect of 
static PET parameters.  Visual inspection of residual plots did not reveal obvious deviations 
from homoscedasticity or normality.  P-values were obtained by likelihood ratio tests of the 
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full model with the effect in question against the model without the effect in question; p-
values < 0.05 were considered statistically significant. 
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5.3 Results 
 
9 patients were included in the study group, with a median age of 66 years (mean 64.2, 
range 59 - 69 years) and a median pre-biopsy PSA level of 7.32 ng/mL (mean 8.16, 
interquartile range 5.03 – 9.76 ng/mL); Table 5.1. The median time from biopsy to PET/CT 
was 57 days (mean 70, range 40 - 189 days), and median time from MRI to PET/CT was 76 
days (mean 87.3, range 45 - 177 days). The median time from PET scanning to surgery was 1 
day (mean 5.78, range 0 - 20 days). 8 studies acquired data to 90 minutes, one study was 
stopped after 60 minutes due to patient intolerance. A total of 13 prostatic tumours were 
present; of these, nine lesions (69%) were in the peripheral zone and four (31%) in the 
transition zone. Four patients (44%) presented with multifocal disease: three patients (30%) 
had tumour foci in both the transition and peripheral zone, while one patient (11%) 
presented with bilateral peripheral zone lesions. Benign prostate hyperplastic (BPH) regions 
could be identified in all participants (100%). 
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Characteristic Value 
Median patient age, years (IQR) 66 (60 – 67) 
Median PSA level, ng/mL (IQR) 7.32 (5.03 – 9.76)   
Gleason score (n = 13)  
3+3 2 
3+4 10 
4+3 1 
4+4  0 
≥9 0 
Pathologic tumour stage (n = 9)  
T2a 0 
T2b 0 
T2c 4 
T3a 4 
T3b 1 
Table 5.1. Patient Characteristics. 13 tumours in 9 patients.   
 
Patients were injected with a median activity of 1192 MBq 11C-acetate (range 912 - 1482 
MBq). The maximum activity released to the atmosphere was 4.6 MBq (mean 2.0 MBq); 
Figure 5.5. The fractional accumulation of the injected 11C was 28.0%, derived as estimate 
activity in soda-lime trap at end of session (range 7.7 – 55%). The mean estimated release of 
activity into the room if there had been no trapping was 50.8 MBq (range 18.5 – 133.4 
MBq); Table 5.2. 
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Figure 5.5. Example stack monitor of gaseous released activity. Patient 9: 59 year old man, injected 
activity 1349 MBq, total gaseous release 2.57 MBq. 
 
 
# Age Administered 
activity (MBq) 
Total gaseous 
release (MBq) 
Fractional 
accumulation 
in trap 
Total decay 
corrected release 
(MBq) 
Estimated 
release if no 
trapping (MBq) 
1 66 912 0.85 47.5% 11.3 33.4 
2 62 1294.1 N/A* 24.2% N/A* N/A* 
3 69 1041.5 4.61 7.7% 24 20.0 
4 67 1481.8 N/A* 21.9% N/A* N/A* 
5 59 1090 1.76 20.1% 14.76 27.9 
6 60 1206.6 0.56 30.0% 2.86 71.4 
7 67 1000.2 2.63 N/A† 13.78 N/A† 
8 69 1304.7 1.33 17.8% 17.94 18.5 
9 59 1349 2.57 55.0% 14.58 133.4 
 
Table 5.2. Activity administered and released. * = could not be calculated as extractor not working 
during these studies; † = activity in the trap not estimated. 
131 
 
 
Time activity curves from the patient cohort corresponding to regions for the normal 
prostate, BPH and tumour regions in the peripheral and transition zones are illustrated in 
Figure 5.6.  Box plots of SUVmax, and SUV60%, for normal PZ, BPH and tumour tissue for all 
time intervals are presented in Figure 5.7. 
 
Figure 5.6a. Time activity curves for patients 1-3. Activity derived from ROIs placed on tumour and 
benign tissue. nPZ = normal peripheral zone (PZ), BPH = benign prostatic hypertrophy, tPZ = PZ 
tumour, tTZ = transition zone tumour. 
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Figure 5.6b. Time activity curves for patients 4-6. Activity derived from ROIs placed on tumour and 
benign tissue. nPZ = normal peripheral zone (PZ), BPH = benign prostatic hypertrophy, tPZ = PZ 
tumour, tTZ = transition zone tumour. 
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Figure 5.6c. Time activity curves for patients 7-9. Activity derived from ROIs placed on tumour and 
benign tissue. nPZ = normal peripheral zone (PZ), BPH = benign prostatic hypertrophy, tPZ = PZ 
tumour, tTZ = transition zone tumour. 
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Figure 5.7. Box and whisker plots for distinguishing tumour from benign tissue. SUVmax (top row) 
and SUVpeak-60 (bottom row) derived from ROIs placed on tumour and benign tissue. nPZ = normal 
peripheral zone (PZ), BPH = benign prostatic hypertrophy, tPZ = PZ tumour, tTZ = transition zone 
tumour. Top and bottom of boxes represent 25th and 75th percentiles of data, line in boxes 
represents the median value and bars representing data within 1.5 times interquartile range, “+” 
denotes outliers. 
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11C-acetate uptake was visualised in the prostate gland in all patients and for all time 
intervals post injection (p.i.); Figure 5.8. Linear mixed effects analysis indicated a statistically 
significant increase in BPH SUVmax and SUV60% values relative to the normal prostate for all 
time intervals considered (SUVmax p = 0.025, 0.023, 0.039, 0.038; SUV60%: p = 0.019, 0.017, 
0.033, 0.018 for 6-10, 14-20, 20-30 and 60-90 minutes p.i. respectively), with increase 
borderline significant on the basis of SUVmean (p=0.052, 0.045, 0.076, 0.063, respectively). No 
age-dependent effects were observed in uptake values of the normal prostate (p=0.44); 
Figure 5.9. 
 
 
 
 
Figure 5.8a. Diagnostic MR imaging and 11C-acetate PET/CT. 59 year old patient, PSA 4.88 ng/ml. 
Diagnostic MRI shows focal low T2 signal bilaterally (left) at the mid gland PZ, larger on the left side 
(arrows), with high signal on b-1400 DWI (centre, left) and early enhancement on DCE (centre, right). 
11C-acetate PET/CT image at the 14-20 minute time point shows increased tracer uptake within both 
lesions. Prostatectomy shows bilateral lesions of grade Gleason 3+4, with established extracapsular 
extension on the left (T3a disease).  
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Figure 5.8b. Fusion of PET/CT to MRI. 59 year old patient, PSA 4.88 ng/ml, bilateral Gleason 3+4 
tumours in the mid gland PZ. 11C-acetate PET/CT image (left column) and fused 11C-acetate PET-MRI 
images (right column) acquired at different time points post tracer injection, showing increased 
uptake within the lesions at the first 3 time-points.   
137 
 
 
 
Figure 5.9. Correlation of patient age to SUVmean uptake in the normal PZ. 
 
 
An increase in values for all SUV metrics was also observed in PCa with respect to normal PZ 
regions. This was significant for all SUV metrics in the 6-10 min interval p.i. (SUVmax: p = 
0.024; SUVmean: p = 0.015; SUV60%: p = 0.018). No statistically significant increases in either 
SUVmax or SUVmean relative to normal PZ were observed for the 14-20 min and 20-30 min 
time intervals. However, SUV60% indicating a stronger effect at all time intervals p.i., 
reaching significance in all but the 20-30 minute time-point (6-10 min: p = 0.018; 14-20 min: 
p = 0.028; 20-30 min: p = 0.052; 60-90 min: p = 0.044). Table 5.3 shows all values acquired 
during the late (60-90 minute) time point. 
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      Normal PZ BPH Tumour 
Patient Location Gleason SUVmax SUVmean SUVp60 SUVmax SUVmean SUVp60 SUVmax SUVmean SUVp60 
1 PZ 3+4 3.353 1.767 2.097 4.288 3.204 4.236 3.291 1.894 2.086 
2 PZ 3+4 1.880 1.710 1.710 3.039 2.595 2.597 2.386 2.041 2.041 
4 TZ 3+3 2.339 1.820 1.833 2.054 1.628 1.651 2.419 1.762 1.860 
4 (lesion 2) PZ 3+4 - - - - - - 2.153 1.944 1.944 
5 TZ 3+4 2.363 1.621 1.680 2.509 1.995 2.016 2.647 1.636 1.967 
5 (lesion 2) PZ 3+4 - - - - - - 2.692 1.842 1.980 
6 PZ 3+4 2.779 2.400 1.440 3.310 2.186 2.531 3.226 2.852 2.852 
7 TZ 4+3 2.436 1.979 1.979 2.044 1.635 1.657 2.986 2.376 2.395 
8 TZ 3+4 1.836 1.303 1.397 2.826 2.084 2.084 2.261 1.842 1.844 
8 (lesion 2) PZ 3+3 - - - - - - 2.731 1.882 2.018 
9 PZ 3+4 2.543 2.089 2.089 2.521 2.040 2.045 3.431 2.588 2.660 
9 (lesion 2) PZ 3+4 - - - - - - 3.223 2.708 2.720 
Group 
mean 
 
- 
 
- 
 
2.441 
 
1.836 
 
1.778 
 
2.824 
 
2.171 
 
2.352 
 
2.787 
 
2.114 
 
2.197 
 
 
Table 5.3. SUV max, mean and peak-60 results per lesion at the 60-90 minute time point. Mean 
values listed; patient 3 did not complete imaging beyond the 60 minute time-point. 
 
 
Classification of lesions into tumours occurring in either the peripheral or transition zone 
revealed statistically significant differences between tumour-PZ and normal-PZ SUV for the 
60-90 min time interval (SUVmax: p = 0.030; SUVmean: p = 0.047; SUV60%: p = 0.041), and 
SUVmax for the 14-20 min period (p = 0.034). Differentiation of tumour-TZ from normal-PZ 
was not achievable on the basis of SUV at the 20-30 and 60-90-time intervals, with 
statistically significant increases occurring at earlier time points (SUV60%: p = 0.018, 0.026 for 
the 6-10 and 14-20 min time periods respectively).  
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Target-to-background ratios (TBR) using SUVmax for both BPH and tumour were compared, 
with normal PZ as the background denominator. For TBR, the max SUV value in the target 
regions (BPH and tumour) is normalised to the mean SUV normal prostate for that time 
interval.  
 
TBR-BPH and TBR-tumour demonstrated high uptake values at all time intervals, and were 
not found to be significantly different from each other (range: p = 0.34 - 0.83). There was no 
significant difference demonstrated between time points for either TBR-BPH (p = 0.85) or 
TBR-tumour (p = 0.63). Discrimination between tumours in the PZ and TZ was also not 
feasible on the basis of TBR-PZ tumour compared to TBR-TZ tumour (p = 0.40, 0.10, 0.87, 
0.37 for 6-10, 14-20, 20-30 and 60-90 min p.i. respectively).  
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5.4 Discussion 
11C-acetate has shown promise as a useful adjunct to current imaging methods for 
assessment of metastatic prostate cancer and recurrent disease [2, 5-8, 21, 22]. However, 
previous studies have shown limited ability of the tracer to distinguish primary tumours 
within the gland from BPH at the 10-20 minute time-point post injection. We tested the 
feasibility of imaging at later time-points to see if clearance of tracer from the blood pool 
and reversible uptake of tracer within prostate tumours could aid primary cancer detection.  
 
An average of 28% of the initial injected activity was trapped within the soda lime canisters 
as exhaled (11C)-CO2, suggesting the majority of the expired activity was absorbed, with a 
mean of only 2.0 MBq gaseous release, representing 1.3% of the initial injected activity. 
Previous work suggests that this trapped percentage is expected: in canine models 23% of 
the injected 11C-Acetate tracer will be exhaled as 11CO2 in first 60 minutes, with the rest 
retained in the body [19], similar results have been noted in man, with the fractional 
recovery of 13C-labelled CO2 after 
13C-acetate infusion being 26.1 % [20]. The local 
Environment Agency permit allows for a daily PET/CT gaseous waste limit of 50 MBq and an 
annual limit of 500 MBq. These limits would be breached without use of the soda lime 
system, with an estimated mean release of activity without trapping being 50.8 MBq.  
 
Differentiation between normal prostate and tumour could be achieved at both early (6-10 
min) and late (60-90 min) time points post tracer administration on the basis of SUVmax and 
SUV60%, but not SUVmean. The SUVmean result may be explained by partial volume effects of 
normal tissue inaccuracies in co-registration of the ROIs from MRI, or tumours having a 
larger anatomical volume compared to their metabolic volume. However, our results did not 
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permit differentiation between BPH and prostate cancer at any time interval post injection.  
 
Analysis of the time-activity-curves demonstrated rapid uptake in all regions, peaking 
approximately 3-10 min post tracer post injection. Regions of BPH tended to exhibit slowly 
decreasing patterns after approximately 10 minutes, whereas both tumours and normal 
prostatic tissue demonstrated a relative plateau phase after the initial peak, followed by a 
gradual decline in radioactivity concentration values at approximately 40 minutes. These 
findings are likely explained by the combined effects of perfusion, acetate metabolism and 
tracer efflux from prostatic tissue. It should be noted that the uptake mechanism of acetate 
in prostate tumours is yet to be fully elucidated. A plateau phase in tumours early after 
injection could be explained by sustained tracer delivery, however, this would not be 
exclusive to any tissue type. Acetate can be utilised by fatty acid synthase (FAS) as well as 
cholesterol synthesis, and predominance of one over the other may vary depending on the 
profile of each individual tumour. It is possible that in tumours with slow glycolytic activity, 
energy requirements are met by increased TCA metabolism due to fatty acid breakdown, 
whereas in others acetate uptake could represent fatty acid or cholesterol synthesis, or 
perhaps a combination of these, depending on the metabolic state of each individual 
tumour. FAS will exist in both normal tissue and BPH, although it will be expected to be 
significantly upregulated in cancer. This could perhaps explain the reversibility of time-
activity-curves at late time points shown both here and in the Mena et al study [7], given 
that TCA and metabolites represent the reversible tissue pool (efflux to the circulation), but 
does not fully exclude the presence of an irreversible compartment in some tumours, 
relating to FAS. 
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11C-acetate PET has been previously investigated for the ability to differentiate tumour from 
benign prostatic tissue. An early study by Oyama et al looked at 22 patients with biopsy 
proven prostate cancer showing a range of SUVmax ranged from 3.27 - 9.87 at 10 – 20 
minutes in tumours; the majority of patients only had TRUS biopsy as the reference 
standard and they did not report benign tissue [8]. Jambor et al did not look at benign 
tissue, but showed no difference in tumour uptake compared to grade in 21 patients, with 
tumours of Gleason grade ≥3+4 having an average SUVmax and SUV60% of 5.5 ±1.1 and 3.9 
±0.9, respectively [5]. Subsequent studies have shown results consistent to our study, with 
variable ability of 11C-acetate to distinguish tumour from normal PZ, but not from BPH. A 
possible explanation for this finding may be an overlap in fatty acid synthase expression 
between tumours, BPH and normal tissue [4]. Mena et al, in a study of 38 patients showed 
than tumour SUVmax at 10-12 minutes (4.4 ±2.05) was significantly higher than normal 
prostate (2.1 ±0.94), but similar to BPH (4.8 ±2.01) [7]. A recent study by Polanec et al 
reported on 40 patients diagnosed with prostate cancer by differing reference tests and 16 
without, showed that 11C-acetate outperformed 18FDG-PET, but with there being no 
significant difference between the SUVmax of tumours (4.6), BPH (5.0) or inflammatory 
prostatitis (4.6) at the 16-20 minute time-point [21]. Earlier work by Kato et al found 
SUVmean at 16-20 minutes in 6 patients with prostate tumours (1.9 ±0.6) to be similar when 
compared to both BPH (2.1 ±0.6) and normal prostatic tissue (2.3 ±0.7) in separate patients 
and volunteers without prostate cancer, with a trend for reduced uptake values in normal 
prostate with age [22]. Similarly, we found SUVmean to be poor at differentiating both BPH 
and prostate tumours from normal tissue. Inherent inaccuracies in ROI definition and image 
registration resulting in partial voluming of normal prostate tissue into BPH and tumour 
ROIs, may help to explain the low discriminative ability of SUVmean. Our results did not 
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indicate a significant effect of age on the SUV of normal prostatic tissue; although the 
current patient cohort is small to draw significant conclusions, the age range reported here 
(58-69 years) is more typical of prostate cancer patient cohorts than the Kato study which 
additionally included normal volunteers of less than 50 years. In terms of tumour pathology 
the two papers using prostatectomy as gold standard [7, 21] had similar distributions to our 
cohort with predominantly Gleason 3+4 tumours, whereas, as expected, the two studies 
that used biopsy as standard and reported on grade had a much higher proportion of low 
grade Gleason 3+3 tumours [6, 8].  
 
5.4.1 Limitations 
Limitations of this study include the small sample size of the patient cohort, and the number 
of lesions investigated.  A further limitation relates to potential translational inaccuracies in 
the region placement due to registration inaccuracies between PET, CT and MR images and 
the possibility of secondary partial voluming effects on the defined ROIs. The clinical MR 
images (in correlation to prostatectomy pathology) were chosen due to their improved 
spatial and contrast resolution and in order to minimise the risk of ROI selection bias for 
regions of increased uptake on PET/CT images. An important challenge in the registration 
process relates to the movement of the prostate, which can occur relative to the pelvic 
bones and neighbouring organs in the pelvis between sequential PET/CT and MRI sessions. 
This may result in an inaccurate alignment of the prostate in MR, CT and subsequently PET 
images, if the registration process is based on an alignment of the pelvic bones alone. 
Furthermore, variable rectal and bladder conditions between the two imaging sessions can 
induce local deformation of the prostate thereby further complicating the image 
registration process. We attempted to mitigate these effects by performing local non-rigid 
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registration of the prostate via the use of a bounding box. Future studies employing 
PET/MRI would serve to overcome this limitation. 
 
5.4.2 Conclusions 
The results from our study show that late time-point (60-90 minutes post injection) imaging 
is feasible using the tracer 11C-acetate and can differentiate tumour tissue from normal 
peripheral zone. However, late imaging could not differentiate tumour tissue from BPH, in 
line with previous studies imaging at early time-points. 
 
5.4.3 Clinical implications 
An advantage of PET imaging is the ability of whole-body functional imaging to provide 
information on node and bone involvement for staging purposes. Any additional ability to 
identify and/or characterise the primary lesion would also be clearly advantageous.  
 
Recently the PET tracer Gallium (68Ga) labelled Prostate-specific membrane antigen (PSMA) 
has been developed. PSMA is a transmembrane protein that is known to be over-expressed 
on most prostate cancer cells. 68Ga-PSMA has shown promise for detection of advanced and 
recurrent prostate cancer and an ability to detect micro-metastatic disease, occult to 
conventional standard of care CT and bone scintigraphy [23, 24]. Recent data suggests that 
68Ga-PSMA-PET may also improve diagnostic yield and localization of primary tumours 
within the gland. On sextant-based analyses, 68Ga-PSMA has been shown to have a 
sensitivity of 67% and specificity of 92% [25] and a similar sensitivity (76%) compared to 
mpMRI (78%), but with a superior specificity (97% versus 79%) [26].  
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The results of our study suggest 11C-acetate PET is unlikely to confer any advantage over 
68Ga-PSMA for primary disease, and further suffers from the disadvantage of needing an on-
site cyclotron for tracer production. However, other potential clinical scenarios may provide 
a niche role. Fatty acid synthase inhibitors have recently been investigated for treatment of 
a number of tumour types, including prostate cancer [27], herein, 11C-acetate may have 
serve as a treatment response biomarker for these novel agents, given the mechanism of 
acetate uptake and metabolism, however, this role would require further investigation.  
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Chapter 6: Thesis summary and conclusions 
 
6.1 Limitations of current technologies  
The PI-RADS version-2 system for mpMRI detection of prostate cancer is based on expert 
consensus opinion and accumulated scientific evidence derived from PI-RADS version-1. The 
test performance of version-2 in research and clinical practise has been shown to be an 
improvement over version-1, maintaining a higher diagnostic accuracy compared to 
standard of care systematic biopsies, as evidenced by the prospective PROMIS trial in the 
UK. Good performance can be attained in practise when the quality of the diagnostic 
process can be assured (including PI-RADS compliant MR imaging protocols, image 
interpretation, reporting and communication, and biopsy procedures), backed up by the 
robust training of radiologists and urologists working jointly within multidisciplinary teams. 
Multiparametric MRI detects the majority of tumours capable of causing harm, with the test 
performance being independent of the exact criteria used to define clinically significant 
disease. However, mpMRI fails to detect all cancers, and will miss around 10% of clinically 
significant cancers, highlighting room for improvement. This thesis assesses potential to 
increase the diagnostic yield of prostate cancer by employing different methods of 
functional imaging. 
 
6.2 Restatement of aims 
Imaging offers great potential for differentiating more aggressive, lethal prostate tumours 
from less aggressive ones. Although MRI with standard clinical sequences has altered the 
paradigm of prostate cancer diagnosis, it has inherent limitations and current guidelines 
actively encourage the development of new sequences. Novel functional MRI and PET 
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techniques to enable more accurate tumour localisation and characterisation were 
evaluated in this thesis. 
 
6.3 Summary of main findings 
Multiparametric MRI is a difficult technique to perform and interpret due to patient, 
tumour, radiologist, and MR scanner related factors. It was demonstrated that preparation 
and patient-related factors can affect the quality of images and attempts should therefore 
be made to control these in order to optimise image quality and outcomes for any MRI 
study performed. 
 
The novel sequences of diffusion kurtosis and magnetization transfer imaging were able to 
readily distinguish benign tissue from tumour, but there was no incremental value over 
standard clinical sequences and none of the measured parameters reliably differentiated 
low and high-grade disease. MTI and DKI showed a correlation to ADC values suggesting that 
cellular density is at least in part contributing to their signal. Interestingly, although both 
parameters showed strong correlation to each other in normal tissue, this was not 
maintained in tumour tissue, suggesting that the sequences impart different and potentially 
complementary information relating to the tumour microenvironment. 
 
An exciting new development in MR imaging is the ability to imaging non-proton nuclei 
within a reasonable time frame and with sufficient SNR to make clinical imaging feasible.  
Sodium MRI is one example of this and, as an important electrolyte in maintaining 
osmoregulation and pH, can potentially offer information on cell membrane integrity and 
tissue viability. Tissue and intracellular sodium concentrations of the prostate were 
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successfully quantified in vivo, with differences shown between the normal PZ and TZ and a 
significantly higher sodium concentration demonstrated within PZ tumours. Further 
developments in hardware and software and/or increasing magnet strength would be 
expected to improve SNR and make this technique more clinically available. The underlying 
physiology of cellular sodium suggests that 23Na-MRI would be ideally suited to monitor 
treatment response, particularly in the setting of ablative focal therapy to the prostate.  
 
11C-acetate PET-CT was investigated as a technique to identify primary tumours within the 
prostate gland as a potential adjunct to its more usual means of assessing nodal or bone 
involvement in more advanced or recurrent disease. Although tumour could not be readily 
differentiated from benign prostatic hypertrophy, it was shown that despite the short 20-
minute half-life of the tracer, late imaging up to 90 minutes was possible and could enable 
differentiation of tumour tissue from the normal PZ. Establishing the feasibility of late 
imaging in this context may allow for further exploration of the role of fatty acid synthase in 
prostate cancer metabolism and will allow for further investigation of the irreversibly 
labelled pool, representing tumour lipid uptake of acetate.  
 
Ultimately if clear benefit is shown for any of the techniques investigated here, for either 
tumour localisation or characterisation, a niche role within the diagnostic pathway will need 
to be established. The pressures of clinical throughput mean that new MRI sequences 
cannot be added to every study performed, and the use of an endorectal coil for sodium 
imaging brings an extra invasive and expensive step. In the short to mid-term a potential 
role could be in assessing for local recurrence post radical radiotherapy. Herein, standard 
clinical sequences are limited and improved localisation of recurrent tumour can enable 
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treatment with salvage focal therapy to the gland. Future development of more specific 
biomarkers such as circulating tumour DNA may provide a further role in problem solving, 
for instance if their results are discrepant with the findings on standard clinical MRI, further 
functional imaging may be warranted. Increasingly attention is being drawn to more 
advanced disease and aggressive treatment options in patients with oligo-metastatic or 
oligo-progressive disease. This area may provide further opportunities for novel PET-tracers 
to assess primary and metastatic disease, or for MR imaging within the pelvic field of view to 
assess high risk patients for locally advanced disease.   
 
6.4 Final conclusions 
It has been shown that novel functional imaging techniques can offer different and 
sometimes divergent information on the tumour and its microenvironment. An incremental 
value for the novel MRI sequences investigated over existing clinical sequences was not 
established for lesion localisation, however, some promise has been demonstrated for 
lesion characterisation. Further work is needed to establish the added benefit and better 
define the role of novel imaging within the diagnostic pathway for prostate cancer.  
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